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ABSTRACT OF THE DISSERTATION
Apolipoprotein E immunotherapy for the treatment of Alzheimer disease and cerebral amyloid
angiopathy
by
Monica Xiong
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2021
Professor David M. Holtzman, Chair

The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for
late-onset Alzheimer disease (AD), a neurodegenerative disorder that leads to cognitive
dysfunction and dementia. One copy of APOE ε4 increases AD risk by 3.7-fold and two copies
by 12-fold, whereas APOE ε2 is protective relative to the more prevalent ε3 allele. APOE4
accelerates the progression of AD by markedly impairing amyloid-β (Aβ) clearance and
promoting excess Aβ aggregation, ultimately resulting in downstream neuroinflammation, tau
pathology, and neurodegeneration. Aggregated Aβ can co-deposit with the APOE protein in the
brain parenchyma as neuritic plaques and in cerebral blood vessels as cerebral amyloid
angiopathy (CAA). The presence of pathogenic APOE may act as a “seed” to promote Aβ
fibrillization, and our lab has previously shown that reducing APOE protein levels with several
genetic approaches in mice results in drastically less Aβ pathology. These findings imply that

xvi

modulating APOE levels, particularly APOE4, directly influences Aβ deposition and may
consequently alter downstream AD neuropathology.
Passive immunotherapy is a relatively feasible strategy that has been tested preclinically
in mice and can be clinically translated in humans. Currently, AD clinical trials using
immunotherapy center on targeting different species of Aβ and tau for degradation. Given that
reducing APOE levels can directly modify Aβ plaque deposition, our lab produced antibodies
targeting murine APOE, which demonstrated efficacy in both prevention and treatment studies.
These promising findings prompted us to ask whether antibodies that bind human APOE, which
have translatable implications, could similarly improve Aβ pathology. We generated a series of
anti-human monoclonal APOE antibodies (HAEs) with varying properties, including binding
affinity for different APOE isoforms, lipidation status, and Fc receptors. One antibody of
particular interest was human anti-apoE antibody (HAE)-4. HAE-4 preferentially recognizes
poorly-lipidated, aggregated APOE3 and APOE4 found in the core of amyloid but not circulating
in plasma. Treatment with HAE-4 in APPPS1-21 mice that express human APOE4 at the onset
of parenchymal plaque pathology resulted in Aβ reductions. The efficacy was dependent on
antibody effector function for the recruitment of activated microglia, as ablating Fc binding
negated any positive effects. Overall, these exciting results suggest that HAE-4 has potential as a
therapeutic candidate for the treatment of amyloidosis in AD. However, one of several pressing
questions that resulted from this study remains: how do APOE antibodies compare to Aβ
antibodies that are currently in clinical trials?
To address this question, it is important to understand that certain Aβ antibodies that are
now being tested are highly effective in reducing amyloid in clinical trials and are now beginning
to show potential effects on slowing cognitive decline, though the effects appear modest

xvii

presumably due to late intervention at a timepoint when events downstream of Aβ have been
initiated. However, these amyloid-removing anti-Aβ antibodies also result in cerebrovascular
adverse effects that are stimulated at high drug doses, namely amyloid-related imaging
abnormalities (ARIA). ARIA is a common neuroimaging finding that is associated with
antibodies targeting aggregated Aβ in individuals with CAA. ARIA manifests as edema (ARIAE) or hemorrhages (ARIA-H) and is thought to result either from accelerated antibody-mediated
clearance of Aβ exiting the perivascular space or from a strong, focal immunological response to
binding CAA. ARIA is sometimes asymptomatic, but a subset of individuals develops headache,
confusion, and focal neurological signs that are usually reversible. While optimism remains high
for Aβ immunotherapy, there is some caution about its generalizability if nearly all AD patients
also have CAA, particularly if the presence of CAA in combination with certain Aβ antibodies is
responsible for ARIA.
Owing to the affinity of HAE-4 to engage only a small but critical core component of
APOE within Aβ plaques, whereas many anti-Aβ antibodies bind to the majority of the protein in
plaques, we hypothesized that APOE antibodies have a somewhat different mechanism of action
compared to Aβ antibodies. We directly compared the effects of HAE-4 to aducanumab, an Aβ
antibody that reduces plaque load in the brain but also induces ARIA in human clinical trials.
Overall, our aims were to investigate the underlying mechanisms of a novel monoclonal antibody
targeting APOE, its ability to ameliorate plaque pathology in the vasculature, and to what extent
CAA-compromised blood vessel function could be restored. To address these questions, we used
5XFAD mice expressing human APOE4+/+ (5XE4) that have prominent CAA and parenchymal
plaque pathology. In chronically treated 5XE4 mice, HAE-4 reduced Aβ deposition including
CAA compared to a control antibody, whereas aducanumab had no effect on CAA. Furthermore,

xviii

aducanumab exacerbated microhemorrhage severity, which strongly correlated with reactive
astrocytes surrounding CAA. In contrast, HAE-4 did not stimulate microhemorrhages and
instead rescued CAA-induced cerebrovascular dysfunction in leptomeningeal arteries in vivo.
HAE-4 not only reduced amyloid but also dampened reactive microglial, astrocytic, and
proinflammatory-associated genes in the cortex. These results suggest that targeting APOE in the
core of both CAA and plaques could ameliorate amyloid pathology while protecting
cerebrovascular integrity and function. Whether HAE-4 exerts its effects through indirect
clearance of Aβ plaques or removal of poorly-lipidated APOE, which may have a gain of toxic
function to promote further seeding of fibrillar plaques, remains a question to be addressed in
future studies. Taken together, our findings argue a paradigm shift away from an Aβ-centric
treatment strategy and towards targeting APOE to treat AD or CAA.
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Chapter 1:
Introduction

1

1.1 Alzheimer disease
As advancements in technology and medicine continue to increase the average life span
of people worldwide, the prevalence of age-related neurodegenerative diseases is escalating at an
alarming rate. Alzheimer disease (AD) is the most common cause of dementia. According to the
World Alzheimer Report, an estimated number of 5.8 million people in the United States
currently have AD, and without a treatment this number is projected to triple by 2050. The
economic burden of AD excluding informal caregiving is estimated at $305 billion in 2020 alone
(Alzheimer’s Association, 2020). These challenges have spurred tremendous research efforts
directed at understanding the complex pathobiology of the disease to pave the way for finding a
cure or preventative treatment for AD.

1.2 Overview: Aβ and CAA pathobiology
1.2.1 The amyloid cascade hypothesis
In 1907, the German psychiatrist and neuropathologist Alois Alzheimer described a series
of symptoms in a patient who presented with a “peculiar” dementia at age 51 that included
memory loss and disorientation (1). This case study became the landmark paper for what is now
known as Alzheimer disease (AD). AD is the greatest cause of dementia, with clinical symptoms
including impairment of behavioral and cognitive functions (2). The earliest pathological marker
in the AD brain is proposed to be the accumulation of Aβ into toxic aggregates that accrue ~20
years before onset of clinical symptoms during the preclinical phase (3, 4). The Aβ peptide is
derived from the proteolytic processing of the amyloid precursor protein (APP) via sequential
cleavage by β-secretase and γ-secretase (5). Aβ is produced in neurons and synaptic activity
modulates its secretion (6, 7). Aβ42, the species commonly found in neuritic plaques, is more
2

prone to self-assemble into toxic, β-sheet conformations of oligomers and fibrils because of its
hydrophobicity (8). The current evidence suggests that Aβ is necessary, although not sufficient,
to initiate AD pathogenesis and drive downstream cellular and molecular changes (9). Aβ
aggregation triggers chronic neuroinflammatory changes and accumulation of phosphorylated
tau into aggregated tau in the form of neurofibrillary tangles, dystrophic neurites, and neuropil
threads, which subsequently drives neuronal cell loss and synaptic alterations (10). Clinical
symptoms are therefore correlated with the rate of tau accumulation in the brain rather than the
rate of amyloid deposition, although the rate of amyloid accumulation predicts onset of tau
accumulation (11). With accruing evidence that Aβ dyshomeostasis plays a central role in
triggering AD, the amyloid cascade hypothesis was proposed as a framework to guide the
development of AD research and treatments (12).
Throughout the decades, the amyloid cascade hypothesis has been challenged and revised
(9, 13). Work supporting the amyloid hypothesis include human genetics studies demonstrating
that mutations flanking the Aβ sequence on the APP gene cause an early-onset, autosomaldominant form of AD that accelerates total Aβ production and Aβ fibrillogenic properties (10).
Meanwhile, a rare APP mutation that decreases Aβ production protects against AD and cognitive
decline (14). The validity of the hypothesis has been questioned particularly when clinical trials
targeting Aβ have failed. However, the results of these trials do not provide substantive claim to
discard targeting Aβ as a therapeutic approach. To adequately translate the successful treatments
from preclinical trials in animals to clinical trials in humans, Aβ-targeting strategies have been
unsuccessful not because the amyloid hypothesis is false, but presumably because of the
interplay between numerous complex factors, including poor target engagement, insufficient
brain penetration, inadequate dosage, adverse effects, misdesigned trials, and delayed
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administration of treatment in clinical trials (discussed in Section 1.4). Despite unsatisfactory
results, these clinical trials have offered novel insight that allows us to adjust our approach and
pave the way for the next generation of therapeutics.
1.2.2 Pathophysiology of CAA
AD and CAA are clinically distinct (15), but they share many molecular features that
interweave the two diseases. The same Aβ peptide that is found in neuritic plaques in AD is also
deposited in the brain vasculature as CAA, which is detected in 85–95% of AD cases (16). The
Aβ peptide was first purified from cerebral blood vessels in AD patients (17), although the
identification of vascular Aβ was first described decades earlier by Gustav Oppenheim in 1909
(18). Whereas Aβ42 and other Aβ peptides are deposited in the extracellular space of the brain as
diffuse or neuritic parenchymal plaques, Aβ40 predominantly deposits in cerebral blood vessels,
potentially as a result of its greater solubility (19, 20). Aβ40 has been linked to the production of
reactive oxygen species (ROS) that impairs functional hyperemia (vascular reactivity) (21) even
before the onset of plaque deposition in young APP transgenic mice (22), suggesting a
predisposition to vascular dysfunction before the formation of plaques. In vitro studies have
demonstrated that Aβ40 with a Dutch type mutation that causes familial CAA self-assembles into
fibrils only on the surfaces of human cerebrovascular smooth muscles, but not during incubation
in solution (23). Despite the preferential deposition of Aβ40 on the vasculature, Aβ42 appears to
be deposited first and is necessary to initially seed Aβ40 into CAA, whereas mice overexpressing
Aβ40 do not develop amyloid pathology (24, 25). These findings are supported by data
suggesting Aβ42 accelerates the nucleation of Aβ40 (26). The toxicity of Aβ accumulation has
spurred the identification of pathways to reduce Aβ production and enhance
degradation/clearance. Currently, four main endogenous mechanisms have been identified to
4

eliminate Aβ from the CNS: [1] enzymatic degradation, [2] receptor-mediated transcytosis, [3]
perivascular drainage, and [4] phagocytosis (27). The pathogenic mechanisms of CAA are not
fully elucidated, but CAA is proposed to primarily result from the failure of the perivascular
drainage pathway to remove Aβ produced by neurons, causing accumulation of Aβ within
basement membranes at the abluminal side of smooth muscle cells in small
leptomeningeal/cortical arteries (24, 28, 29). This impaired clearance drives a vicious, selfreinforcing cycle of vascular and parenchymal Aβ accumulation that can exacerbate AD.
Sporadic CAA is a disease predominantly of leptomeningeal arteries and penetrating
arterioles that causes spontaneous intracerebral hemorrhage and age-related cognitive decline
(30). There are two types of CAA: type 1 is characterized by CAA deposition in cerebral blood
vessels including leptomeninges, arteries, arterioles, and to a lesser extent capillaries; type 2
excludes CAA in capillaries (31). CAA is a fairly common pathological finding in elderly brains
without AD (16) and worsens cognitive decline in AD (32). Clinically, probable CAA is
diagnosed upon identification of multiple cortical and/or subcortical hemorrhages in the elderly
using the Boston Criteria, an imaging diagnostic criteria (33). Similar to AD, a diagnosis of CAA
is currently confirmed only through postmortem pathological assessment of brain tissue.
Functionally, CAA-burdened vessels have degenerative vessel walls with microaneurysm
formation (30), thereby impairing crucial vascular functions such as the delivery of
oxygen/nutrients and solute efflux (i.e. Aβ) from the brain (34). Aβ may also reduce cerebral
blood flow by neutrophil adhesion and blockage in brain capillary segments (35). Although
soluble Aβ monomers compromise vessel responses to vasoactive stimuli in vascular endothelial
cells (22, 36), fibrillar Aβ in the form of CAA, particular severe CAA, causes much more severe
vessel dysfunction that can eventually lead to the loss of vascular smooth muscle cells (37). The
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trauma imposed on the cerebrovasculature can induce three main types of CAA-associated
bleeding: 1) symptomatic intracerebral hemorrhage, 2) microbleeds/microhemorrhages, and/or 3)
cortical superficial siderosis (38). These CAA-associated bleeds and subsequent brain injuries
impair cognition that is independent of AD and other pathologies. In summary, accumulation of
Aβ in the vasculature can compromise vascular cells (39), render vessels functionally
irresponsive to normal physiological events (40), and cause perivascular drainage failure (41), all
of which may accelerate the progression of AD and cause symptomatic cognitive impairment.

1.3 APOE polymorphism as a risk factor for AD and CAA
1.3.1 Interactions between APOE and parenchymal Aβ in AD
Although many genetic factors confer increased sporadic AD risk, by far the strongest
genetic risk factor is the ε4 allele of the apolipoprotein gene (APOE4) (42). Human APOE is a
299 amino acid lipoprotein that harbors an important role in lipid and cholesterol transport (43).
In the periphery, APOE is produced by the liver and macrophages (44), a pool of APOE that
does not bypass the BBB under normal conditions (45). Therefore, the central nervous system
(CNS) produces its own pool of APOE, mostly by astrocytes, and partially by microglia,
pericytes, smooth muscle cells, and injury-stressed neurons (46). APOE is lipidated with
cholesterol and phospholipids by the cell-surface ATP-binding cassette transporter (ABCA1)
before secreted from cells (47). The central role of APOE is to redistribute these lipids to cells
via binding to APOE receptors, which are expressed by neurons, astrocytes, and microglia in the
brain and belong to the low-density lipoprotein receptor (LDLR) family, including LDLR and
LDLR-related protein 1 (LRP1) (27).
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There is an isoform-dependent effect of APOE on AD. A single copy of APOE4
increases the risk of developing AD by 3.7-fold and two copies by 12-fold relative to the more
prevalent ε3 allele (48). Additionally, APOE4 accelerates the progression of AD by decreasing
the age of onset (49) through several potential mechanisms, including reducing Aβ clearance
from the brain and increasing the propensity of Aβ to aggregate (50). Conversely, APOE2 is
protective against developing AD compared to APOE3 (51, 52). Between the three major APOE
isoforms, there is a single amino acid difference: APOE3 contains Cys112, Arg158; APOE2
contains Cys112, Cys158; APOE4 contains Arg112, Arg158. This single residue substitution is
speculated to determine key properties of the protein, including the structural instability that
results in the pathogenic effects by APOE4. Resolving the structure of lipidated APOE would
greatly assist in understanding the lipid dynamics, folding process, receptor binding of APOE,
and interactions with other proteins such as Aβ (53). Apart from AD, APOE4 is also associated
with increased risk for other diseases (43), including cardiovascular disease (54), CAA (55),
Down’s syndrome-associated dementia (56), synucleinopathy (57–59), and primary tauopathies
(60–62) – all of which strengthens the importance of understanding the multifaceted role of
APOE on lipid homeostasis/transport, cerebrovascular function, glucose metabolism, innate
immunity, and more.
Aβ deposition is regulated in an APOE-isoform dependent manner. Studies in APP
transgenic mice crossed with the targeted replacement human APOE2, APOE3, APOE4 mice
(63) reveal an APOE isoform-dependent increase in Aβ pathology (50, 64, 65) that mimics the
Aβ deposition pattern seen in humans (66). Notably, amyloid load in APOE4 carriers as
measured by Pittsburgh compound B (PiB) is higher compared to APOE3 years before the onset
of cognitive decline (50), suggesting a relationship between APOE4 and amyloid accumulation
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irrespective of the dementia due to AD. In a remarkable recent discovery, one individual who
harbored the presenilin 1 (PSEN1) mutation and two copies of APOE3 with the Christchurch
(R136S) mutation demonstrated resistance to early clinical onset of AD, similar to the effects of
APOE2 (67). This prompts questions about Aβ-APOE interactions. Studies have shown that
there is a direct interaction between APOE and Aβ, as APOE is detectable within amyloid
plaques (68). Previous work has implicated that APOE acts as a chaperone protein for Aβ to
form APOE-Aβ complexes to facilitate clearance. For example, APOE2 and APOE3 rapidly
cleared Aβ by LRP1 (fast) and VLDLR (slow) at the BBB, whereas APOE4 redirects binding to
VLDLR, which internalizes APOE-Aβ complexes at the BBB at a substantially slower rate than
LRP1 (69). However, one study suggests that there are minimal physiological soluble Aβ and
APOE interactions, and that APOE modulates Aβ by competing for LDL receptor-mediated
clearance (70). Indeed, overexpression of LDLR also accelerated Aβ clearance (71, 72) through
APOE-dependent and -independent pathways (71–73). Previous findings have also revealed that
the lipidation state of APOE is also critical for pathological Aβ progression. Specifically,
knockout of the Abca1 gene in mice resulted in production of poorly lipidated APOE. When
these mice were crossed to mice expressing human APP, this resulted in increased Aβ
deposition, whereas the overexpression of Abca1 decreased Aβ load (74, 75). This suggests that
poorly lipidated APOE promotes Aβ seeding and more lipidated APOE inhibits Aβ seeding. In
humans, APOE4 carriers have more lipid-depleted APOE in the cerebrospinal fluid (CSF)
compared to non-APOE4 carriers (76). Meanwhile, overexpression of Abca1 or treatment with
drugs that increase APOE lipidation strongly reduces Aβ plaque deposition in APP transgenic
mice (77, 78).
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Although the detailed underlying mechanism is not completely clear, APOE has a
seemingly contradictory role in amyloidosis that may result from a loss of protective function or
gain of toxic function. As discussed previously, APOE interacts with Aβ peptides to increase
fibrillogenesis and reduce clearance (50) during the initial phase of plaque accumulation (79).
The absence of APOE reduces Aβ42 aggregation in vitro (67). These findings suggest that
perhaps deletion of APOE may be protective. However, although APP transgenic mice that were
APOE-deficient lacked dense-core, amyloid plaques that are typically associated with damage to
adjacent axons and dendrites (80), complete APOE deficiency increased swollen dystrophic
neurites around the very few fibrillar Aβ plaques present (81, 82). These findings suggest a
protective role for at least having a small amount of APOE and/or microglia (via TREM2) to
compact diffuse-like plaques into fibrillar structures and limit toxicity (82–84). Further support
for the protective function for APOE is demonstrated in other studies showing ablating APOE in
mice resulted in synaptic loss during aging (85) and heightened oxidative stress in the brain (86).
Despite these studies in vitro and in transgenic mouse models, APOE deficiency in a 40-year-old
individual had remarkably no impact on cognitive function (87). However, the long-term effects
of APOE deficiency are unknown, whereas reducing the gene dosage of APOE3 and APOE4 is
known to also concomitantly reduced Aβ plaque pathology in mice (88). Given that the role of
APOE4 is undoubtedly detrimental in AD, focusing on APOE4 therapeutics rather than complete
removal of APOE may be a safer, more conservative approach as more basic research further
unravels the role of APOE on Aβ and downstream biological system. Taken together, these
findings are suggestive that potentially an APOE-based immunotherapeutic approach may be
beneficial in both reducing APOE and Aβ load.
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1.3.2 Interactions between APOE and vascular Aβ in CAA
The heterogeneity of Aβ deposition in parenchymal tissue as well as various types of
blood vessels can complicate the interpretation of the effects of APOE on parenchymal Aβ
versus vascular Aβ. The overlap in the two diseases is exemplified by neuropathological data
demonstrating most AD patients bear varying degrees of CAA. As APOE4 was described earlier
to impair and/or compete with Aβ for clearance, it is not surprising that APOE4 plays a crucial
role in CAA development, prevalence, and severity. There are mixed reports of the association
between APOE4 and CAA in AD (89), although the general consensus is that APOE4
exacerbates CAA in patients with or without AD (52, 90–92). In APOE4 carriers without AD,
the first hemorrhage was detected five years earlier compared to APOE3 carriers, suggesting an
acceleration of CAA and CAA-related hemorrhages that was independent of AD (55). APOE4
increases the prevalence and severity of CAA in leptomeningeal arteries and arterioles in certain
regions such as the occipital lobe, neocortex, and meninges (32, 93). Severe CAA, which is
marked by extensive amyloid deposition with vasculopathic changes, is found in 73.4% of
APOE4 homozygous carriers compared to 24.2% in APOE3 homozygous carriers (94).
Furthermore, APOE4 is associated with CAA Type 1 (involvement of CAA in the capillary) (95)
and poorer cognitive decline, attributed to numerous factors, including increased prevalence of
intracerebral hemorrhages (ICH) (55, 96), impaired cerebral blood flow (97), etc. Although
APOE2 is not a risk factor for CAA development, APOE2 is associated with more hemorrhages
if CAA is present (96), potentially because of the low binding affinity of APOE2 to LDLR which
reduces lipid efflux and the development of hyperlipidemia (98). Recently, one study discovered
that APOE2 was associated with CAA, specifically in the leptomeninges with cortical superficial
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siderosis (surface bleeding), while APOE4 was associated with cortical CAA and microbleeds
(penetrating bleeding) (38).
Aβ not only colocalizes with APOE in the parenchyma, but APOE and aggregated Aβ
also co-deposit in the vasculature. APP transgenic mice expressing human APOE isoforms
exhibited more CAA with APOE4 and a shift towards greater Aβ 40/42 levels which favors the
development of CAA compared to APP transgenic mice with murine Apoe or APOE3 (99).
Deletion of the Apoe gene from APP transgenic mice completely prevented the formation of
CAA and CAA-related microhemorrhages, demonstrating that Apoe is necessary for the
development of CAA (100).
There appears to be crosstalk between lipid metabolism, the neuroimmune response, and
CAA that is driven by APOE. Abca1 KO mice have increased vascular amyloid and CAArelated hemorrhage despite reductions in soluble APOE protein (101, 102). Indeed, a loss-offunction mutation in ABCA1 was linked to low levels of plasma APOE and increased risk of AD
and cerebrovascular disease (103). This is likely due to lipid-poor APOE being more
amyloidogenic for vascular Aβ deposition and being more readily sequestered into vascular
plaques. APOE4 is also associated with a subtype of CAA related brain disease, spontaneous
CAA-related inflammation (CAA-ri), which manifests as inflammation associated with vascular
Aβ deposits and perivascular infiltrates (104). The production of anti-Aβ autoantibodies in CAAri elicits an immune reaction with clinical and neuroimaging features resembling amyloid-related
imaging abnormalities (ARIA), an adverse side effect that develops secondary to amyloidtargeting antibodies particularly in APOE4 carriers (46, 105). ARIA is postulated to arise as a
consequence of anti-Aβ antibodies binding to Aβ in CAA and eliciting an immunological
response to CAA with failed Aβ clearance, resulting in leakage events resulting from the
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immune response. These data suggest that APOE4 may provoke an inflammatory response in
CAA. Taken together, the research findings thus far are strongly suggestive for an interactive
effect of APOE genotype and vascular Aβ that exacerbates AD and CAA pathology.
1.3.3 Interactions between APOE and cerebrovascular dysfunction
Emerging neuropathological, neuroimaging, and biomarker studies demonstrate that there
are APOE4-modulated vascular contributions to cognitive dysfunction that may precede
neurodegenerative changes. The presence of APOE4 in the cerebrovasculature has been shown
to reduce cerebral blood flow, increase the permeability of the blood-brain barrier (BBB), and
exacerbate CAA by damaging the neurovascular unit (brain endothelial cells, pericytes, and
astrocytes) (46), all of which may contribute to accelerated cognitive decline in AD-dependent
and -independent pathways (106). Functional brain changes are captured with various imaging
methods, including blood oxygen level-dependent (BOLD) MRI response as a proxy for neural
activity and pulsed arterial spin labeling MRI (ASL-MRI) for direct CBF measurements.
Cognitively normal APOE4 carriers demonstrated brain region-specific overactivity when young
with a disproportionate reduction in brain activation and CBF during aging (107, 108). Changes
in the BOLD response and CBF suggest underlying changes in neurovascular relationship altered
by APOE4.
APOE4 is associated with a defective blood-brain barrier (BBB), which normally limits
the entry of large molecules and toxic blood-derived proteins. In cognitive unimpaired
individuals, compared to the APOE3 homozygotes, APOE4 carriers have earlier BBB breakdown
in the hippocampus and medial temporal lobe when Aβ/tau effects are excluded (109). BBB
defects are enhanced in APOE4 carriers in AD patients and exhibit extensive extravasation of
plasma products (110), cerebral microbleeds (111), and microvascular basement membrane
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injury (112). Interestingly, mice lacking APOE also have heightened extravasation in the brain
and spinal cord (113), suggesting a potential protective function for APOE in maintaining the
BBB. Recent interest in pericytes, which maintain the BBB at the capillary level and act as
contractile cells in place of smooth muscle cells, show degeneration in AD (114) and more so in
APOE4 carriers (115). One study recently identified elevated BBB permeability and capillary
damage measured by increases in soluble PDGFRβ (sPDGFRβ) in the CNS that is associated
with early cognitive impairment independent from Aβ and tau accumulation (116), supported by
in vitro data from another group showing that APOE4 pericytes impaired basement membrane
formation (117). Furthermore, overproduction of APOE4 derived from pericytes in a threedimensional culture system appears to capture more vascular Aβ in capillaries (118). In APOE4
carriers, the elevated levels of CSF sPDGFRβ, an injury marker of pericytes, is correlated with
cyclophilin A and matrix metalloproteinase-9 (109), a proinflammatory pathway in pericytes that
leads to deleterious effects on basement membranes and tight junctions (119). These findings
suggest that at the capillary level, APOE4 pericytes have a partial loss-of-function in protecting
the brain vasculature.
Cerebral microhemorrhages is one form of vascular damage that is more commonly
found in individuals with vascular conditions, for example hypertension, stroke, diabetes,
retinopathy, and CAA (120, 121), but also in individuals participating in clinical trials with
certain passive immunotherapy against Aβ, which can have varying degrees of symptomatic
manifestation. APOE4 is a risk factor for more frequent and accelerated cerebral microbleeds
(122, 123). In the elderly population, cerebral microbleeds are associated with cognitive
impairment and dementia, particularly in individuals with multiple microhemorrhages (121, 124,
125). In AD, there is lobar distribution of cerebral microbleeds that corresponds with the
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topographic distribution of CAA (126). CAA is present in >90% of AD patients, therefore it is
no surprise that there is a higher proportion of microhemorrhage events in AD compared to nondemented individuals (126, 127). Although the exact mechanism of APOE4 on cerebral
microhemorrhages in AD is not clear, there are likely shared contributions from an overall
increase in CAA and BBB dysfunction that lead to vascular damage and bleeds. Taken together,
these findings demonstrate that in AD-dependent and -independent pathways, APOE4 takes a
spotlight role in exacerbating cerebrovascular dysfunction.

1.4 Aβ-modifying therapeutics in AD
1.4.1 Approved FDA drugs for the treatment of AD
Currently, the U.S. Food and Drug Administration (FDA) has approved four prescription
drugs for the management of AD symptoms. These include three cholinesterase inhibitors
(donepezil, galantamine, rivastigmine) and one NMDA receptor antagonist (memantine)
(Alzheimer’s Association, 2019). Although there is no effective disease-modifying therapy yet,
enormous strides have been made to develop novel therapeutics that may treat or prevent AD in
the future.
1.4.2 Overview of current AD therapeutics targeting Aβ
Therapeutic approaches targeting Aβ are at the forefront of disease-modifying strategies
to treat AD. The rationale stems from the amyloid cascade hypothesis, in which eliminating Aβ
may be sufficient to halt cognitive impairment and/or prevent downstream tau-mediated toxicity
and neurodegeneration. Previously, most of these therapies in development were small
molecule/compounds that modulate Aβ production via secretases. The small molecule
development targeting Aβ production through β or γ-secretase inhibition has stopped for now
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due to side effects of inhibiting these enzymes. However, there are still many immunotherapies
in development promoting clearance of Aβ or tau. Since the first active Aβ immunotherapy, Aβ
antibodies have evolved and been optimized over the past two decades through lessons learned
from clinical trials that have yet to get an approved approach. However, there are some
promising results from phase 2 trials and one phase 3 trial with at least three different antibodies
in potentially slowing cognitive decline in mild AD.
The first Aβ-targeted treatment that moved to clinical trials for AD was a vaccine towards
an Aβ42 peptide (AN1792), with the rationale that an immune response would be induced
towards the injected immunogens for brain amyloid removal (128). In humans and mice, active
immunotherapy with AN1792 reduced Aβ deposition (129, 130). However, clinical trials were
halted in phase 2 due to the development of meningoencephalitis in a subset of participants,
presumably from T-cell reactivity against Aβ (130, 131). Post hoc analysis revealed that even in
a subgroup of responders with substantial serum anti-Aβ antibody titers, there were no effects on
cognition (131), although the study was not powered to address efficacy.
To minimize neuroinflammatory responses, therapeutic strategies have turned to the
usage of passive immunotherapy targeting Aβ that is infused systemically (9, 131). Two of the
first anti-Aβ antibodies tested in clinical trials were solanezumab (m266) (132) and
bapineuzumab (3D6) (133, 134), two antibodies with highly different binding targets and
mechanisms of action. Solanezumab has a high affinity for soluble, monomeric Aβ (rather than
aggregated Aβ or Aβ plaques) and exerts its beneficial effects by shifting the Aβ equilibrium
from the brain to plasma, also known as the “peripheral sink” hypothesis (132) or by lowering
soluble Aβ in the CNS directly. Solanezumab has also been shown to be detectable in CSF,
suggesting it may exert its effects locally in the brain as well (135). Although solanezumab did
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not meet end point goals for cognitive decline in two large-scale phase 3 trials, secondary
analysis of patients with only mild AD showed cognitive benefits with minimal adverse effects
(136). However, a third phase 3 trial with solanezumab did not affect cognitive decline
meaningfully (137).
Bapineuzumab targets the N-terminal region of Aβ, which included both soluble and
fibrillar Aβ and reduced plaques by microglial phagocytosis. There are mixed reports of efficacy
in mice (134, 138). In two phase 3 clinical trials, there were no improvements in cognitive
dysfunction, although biomarker analyses uncovered treatment differences in Pittsburgh
compound B positron emission tomography (PiB-PET) and CSF phospho-tau (p-tau) in the
APOE4 carriers (139, 140). The biggest issue with these two studies is that dosing was never
elevated to high enough levels to result in significant amyloid lowering in the brain. The major
safety finding was amyloid-related imaging abnormalities (ARIA) with edema and
microhemorrhages, which was more severe in individuals with one (11.4%) versus two (27.3%)
copies of APOE4 and administered high doses of bapineuzumab (139). Possible explanations for
the lack of efficacy of bapineuzumab include discontinuation of the high dose group due to
ARIA (139), late-stage treatment, and most importantly, dosing was not enough to markedly
lower amyloid deposits. Although the mechanism for ARIA is unknown, it is postulated that
either (1) inflammatory activation of immune cells on CAA compromises vascular integrity, or
(2) clearance of Aβ plaques shuttles toxic Aβ through the perivascular pathway to disrupt the
vasculature. To reduce the risk of ARIA, antibodies such as crenezumab were engineered on an
immunoglobulin (IgG) backbone with low affinity for Fcγ receptors, thereby reducing immune
activation (141). Indeed, crenezumab reduced oligomeric Aβ and was well-tolerated (142), but it
also did not meet primary outcomes. It also did not significantly lower amyloid load in the
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human brain at the doses utilized. Numerous other Aβ antibodies have been developed targeting
different forms of Aβ, including aducanumab (143). Recently, in one of two phase 3 trials,
aducanumab markedly reduced amyloid burden and slowed cognitive decline in a subgroup
analysis (144). In the second trial, there was reduced amyloid burden but no significant slowing
of cognitive decline. In both trials, transient ARIA was detected in ~40% of participants
receiving the highest dose, and 19.7 – 29.1% of those in this subgroup was symptomatic with
headache, dizziness, visual disturbances, and/or nausea/vomiting (144). Currently, the FDA is
reviewing the application for aducanumab to potentially become the first disease-modifying
treatment for AD.
The lack of efficacy of certain humanized monoclonal Aβ antibodies could result from
numerous interacting factors. One commonly cited explanation is the inadequate dosage that is
administered to counterbalance minimizing adverse side effects (ARIA) while maximizing Aβmodifying effects. Interestingly, in recent gantenerumab trials, ARIA was depicted to mark
hotspots of substantial amyloid removal (Alzforum.org), perhaps giving credence to the
necessity of an effector function that rapidly facilitates amyloid clearance. Another explanation
for the unsatisfactory results is the late timing of the interventions. Although mild cognitive
impairment (MCI) represents an intermediate phase of the clinical disease, biologically the
disease has advanced to a late stage. Reducing Aβ at an advanced stage of the disease when taumediated neurodegeneration has already damaged the brain may be too late in the disease
process to modify clinical outcomes. To address this late-timing concern, new therapeutic
strategies are now targeting early interventions in a series of secondary prevention trials aimed at
pre-symptomatic, healthy individuals who are genetically at-risk (145). Recently, the
Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) prevention study in
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asymptomatic autosomal-dominant AD mutation carriers tested two arms with solanezumab and
gantenerumab. Although the DIAN-TU trial did not achieve its primary cognitive endpoint,
gantenerumab showed robust biomarker effects by reducing amyloid PET and increasing CSF
Aβ42, reducing tau and p-tau, and decreasing neurofilament light (146). These data are
particularly exciting because they support the amyloid hypothesis – altering amyloid can
improve downstream markers of tau and neurodegeneration. Furthermore, the asymptomatic
participants did not decline over four years. The lack of overall clinical benefit of gantenerumab
is ascribed to the late introduction of high doses as well as the small trial sizes but more
importantly, not enough patients were followed for long enough that clinically declined. What
would happen if participants were given sufficient, higher antibody doses? Would altering
biomarkers in the right direction correlate with beneficial clinical outcomes? These questions
will hopefully be answered in the ongoing DIAN open-label extension (DIAN-OLE) trials.
Future DIAN-TU Next Generation trials are planning to test treatments against tau using a tau
antibody, gene therapy, and an aggregation inhibitor (www.clinicaltrials.gov).
Recently, the results from two Aβ antibodies in phase 2 trials are re-energizing the field
and inspiring hope for an effective disease-modifying treatment in the foreseeable future. The
rationale behind the production of lecanemab (BAN2401) stemmed from the observation that
PiB retention of insoluble, fibrillar plaques was surprisingly low in APP Arctic mutation carriers
that developed AD, but instead there was enhanced formation of toxic Aβ protofibrils (147, 148).
Lecanemab was therefore designed to bind soluble Aβ protofibrils. Treatment with lecanemab in
preclinical trials showed reductions of Aβ protofibrils in both brain and CSF (149). In a phase 2b
trial, the group receiving the highest dose of lecanemab showed reduction of amyloid and
slowing of cognitive decline (www.alzforum.org). Similarly to other Aβ antibodies that target
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aggregated Aβ, the major adverse effect was ARIA, which resolved in less than three months.
These promising results initiated two phase 3 trials to test the efficacy of lecanemab in
participants with no cognitive impairment who have elevated brain amyloid both below and
above the positivity threshold, as well as in participants with early, symptomatic AD
(www.alzforum.org). These trials will run for the next few years. Another antibody that has
demonstrated recent success is donamemab (N3pG), which recognizes a pyroglutamate form of
Aβ deposited specifically in amyloid plaques. Preclinical studies with this antibody showed
clearance of pre-existing plaques without eliciting microhemorrhages (138). In a phase 2 trial,
donanemab slowed cognitive decline and reduced amyloid in participants with early cognitive
impairment, although a quarter of the participants developed ARIA despite no exacerbation of
microhemorrhages being previously detected in mice (www.alzforum.org). Currently,
donanemab is being tested in another clinical trial testing safety and efficacy with early AD that
will run until 2024. Taken together, the recent findings from these two antibodies suggest that
Aβ antibodies when given at high enough doses are showing beneficial effects in mild AD,
although they all have some degree of ARIA.
Next generation therapeutic strategies are now targeting early intervention and novel
targets, including APOE, inflammation, and lipid metabolism using various methods such as
passive immunotherapy, small molecules, and gene therapy. At the preclinical level, APOE4targeting therapeutics have shown success by altering disease progression [for review, see review
(150)]. A disease-modifying treatment that can remove substantial amyloid while maintaining an
acceptable safety profile is key for clinical outcomes.

19

Chapter 2:
Targeting of nonlipidated, aggregated APOE
with antibodies inhibits amyloid
accumulation

This chapter is adapted from the following manuscript
Liao, F.*, Li, A.*, Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser,
J., Lefton, K. B., Robinson, G. O., Serrano, J. R., Silverman, A. P., Guo, J. L., Getz, J., Henne,
K., Leyns, C. E. G., Gallardo, G., Ulrich, J. D., Sullivan, P. M., Lerner, E. P., Hudry, E.,
Sweeney, Z. K., Dennis, M. S., Hyman, B. T., Watts, R. J., & Holtzman, D. M. (2018). Targeting
of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. The Journal of
Clinical Investigation, 128(5), 2144-2155.
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2.1 Summary
Apolipoprotein E (APOE) is the major susceptibility gene for sporadic, late-onset
Alzheimer disease (AD). APOE strongly influences the development of Aβ pathology through
several potential mechanisms, including modulating amyloid-β (Aβ) clearance from the brain
and the propensity of Aβ to aggregate. Notably, APOE is also detectable within amyloid plaques.
Our current study investigated the therapeutic effects and underlying mechanisms of anti-human
APOE antibodies (HAEs) that specifically recognize human APOE isoforms. One particular
APOE antibody (HAE-4) recognized poorly-lipidated, aggregated human APOE3 and APOE4
but not native APOE particles found in circulation. In APPPS1-21 mice expressing human
APOE4, HAE-4 significantly reduced Aβ deposition without altering APOE levels in the
periphery or brain, suggesting that HAE-4 recognized a minor subportion of APOE. An acute
peripheral treatment with HAE-4 revealed increases in plaque-associated staining of the
activated microglia marker CD45, suggesting a role of microglia phagocytosis for the clearance
of Aβ plaques. Ablating the Fcγ receptor function negated the efficacy of HAE-4, suggesting that
intact effector function to elicit a microglial response is necessary for the reduction of amyloid
pathology. Our findings suggest that targeting the clearance of Aβ plaques with specific antiAPOE antibodies may serve as a viable therapeutic strategy for treating AD.
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2.2 Introduction
Alzheimer disease (AD) is the most common form of dementia characterized by
extracellular amyloid-β (Aβ) protein accumulation and intracellular neurofibrillary tau tangles.
The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset AD,
particularly the ε4 allele of human APOE (APOE4). APOE4 has also been shown to be a risk
factor for many neurodegenerative diseases including primary tauopathies (corticobasal
degeneration, Pick disease, progressive supranuclear palsy) (62) and synucleinopathy (58). In the
central nervous system, APOE is produced predominantly by astrocytes and microglia under
physiological conditions and is lipidated by the transporter ABCA1 (44). It is then secreted into
the interstitial fluid (ISF) and mediates lipid transportation between cells. Aβ is produced in
neurons and secreted into the ISF, where aggregated Aβ binds to APOE such that APOE can be
found in the core of Aβ plaques (68). Although APOE plays roles in other neurodegenerative
diseases that are still unclear, APOE has been shown to exacerbate Aβ pathogenesis by
promoting Aβ fibrillation (151) and impairing Aβ clearance (50). Our group has also shown that
reducing APOE gene dosage resulted in decreased Aβ deposition (88), suggesting that lowering
APOE protein levels could attenuate Aβ pathology. Thus, we hypothesized that enhancing APOE
degradation with passive immunotherapy may be an effective therapeutic approach for the
treatment of amyloidosis.
Previously, our lab has shown that passive immunotherapy targeting endogenous mouse
APOE reduced Aβ pathology in mouse models of amyloidosis when administered peripherally
both before (152) or after the onset of plaque deposition (153) in mouse models of amyloidosis.
To translate this approach into a potential therapeutic in humans, we generated antibodies
targeting the human isoforms of APOE to test in a mouse model of amyloidosis. We also
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investigated the mechanisms underlying the differential effects of the anti-human APOE
antibodies (HAEs). Our results suggest that HAE-4 facilitates the decrease of Aβ accumulation
by targeting a poorly-lipidated conformation of APOE found within Aβ plaques.

2.3 Experimental methods
Animals. All animal procedures and protocols were approved by the Animal Studies Committee
at Washington University School of Medicine. APPPS1-21 transgenic mice [APP
(KM670/671NL)/PS1 (L166P)] under the control of a Thy1 promoter on a C57BL/6 J
background were crossed with APOE4 knock-in mice with APOE under the control of
endogenous mouse regulatory elements on a C57BL/6 J background. APOE4 knock-in mice
were provided by Dr. Patrick M. Sullivan (Duke University). EKO mice were purchased from
Taconic. APPPS1-21/APOE4 All mice were housed in standard cages under pathogen-free
conditions on a normal 12-h light/dark cycle with ad libitum access to food.
Antibody generation. The HAE antibodies were generated by injecting recombinant apoE4 with
complete Freund’s adjuvant into mice. For an initial screening of antibodies, supernatants from
hybridoma cells were added to 96-well plates coated with recombinant apoE4 and the HAE that
bound to apoE4 was detected using anti–mouse IgG HRP. The antibodies that performed well in
the initial screening were further characterized and selected for in vivo studies. For the in vivo
study, antibodies were generated from cultured hybridoma cells and purified on a protein G
column. All HAE antibodies utilized in vivo contained similar amounts of endotoxin as
compared with control antibodies. All four anti–APOE antibodies investigated are mouse
immunoglobulin (IgG). HAE-1 is an IgG1. HAE-2, HAE-3, and HAE-4 are IgG2ab subtypes.
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Tissue harvesting. Mice were anesthetized with pentobarbital (200 mg/kg, i.p.) and
transcardially perfused with cold PBS containing 0.3% heparin. One hemibrain was dissected,
flash-frozen on dry ice, and stored at –80 °C for biochemical analyses. The other hemibrain was
fixed for 24 – 48 hours in 4% paraformaldehyde and cryoprotected in 30% sucrose at 4 °C.
Immunohistochemistry and quantification. Brains were sectioned coronally at 50 µm using a
freezing, sliding microtome (Leica) and stored in cryoprotectant solution (0.2 M PBS, 15%
sucrose, 33% ethylene glycol) at –20 °C. For all histological studies unless otherwise stated,
three sections were stained from each mouse separated by 300 µm (bregma −1.5, −1.8, and −2.1
mm) at room temperature and on a shaker as previously described(62, 154). Antibodies for
immunostaining for Aβ include biotinylated anti-Aβ1-13 monoclonal antibody HJ3.4B (produced
in-house, 2 µg/mL) and activated microglia using rat anti-CD45 (Biorad, MCA1388, 1:500) with
goat anti-rat IgG secondary antibody (Life Technologies, A10517, 1:1000). Stained brain
sections were scanned with a Nanozoomer 2.0-HT slide scanner (Hamamastu Photonics) and
quantified using Fiji software version 1.52v (ImageJ). The percent area covered by staining was
calculated by tracing the cortex overlaying the hippocampus. Three brain sections per mouse
were averaged for an individual biological replica.
Immunofluorescence. The staining protocol was performed at room temperature and on a
shaker unless otherwise noted. Fixed tissue. Free-floating brain tissue sections were rinsed (3 X
5 min) and permeabilized in 0.25% triton-X-100 in TBS (TBS-X) for 30 min. Sections were then
incubated in X34 dye that was prepared in X34 buffer (40% ethanol in TBS) for 30 min. The
tissue sections were de-stained with X34 buffer (3 X 2 min) and TBS (3 X 5 min). If primary
antibodies were used, slices were then blocked in 3% donkey or goat serum in TBS-X before
incubating overnight in primary antibodies with 1% serum in TBS-X at 4 °C. The following day,
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tissue sections were rinsed (3 X 5 min) and incubated for 1 hour in secondary antibody in TBS.
After washing, brain sections were mounted on slides and cover-slipped with Fluoromount-G
Mounting Medium (Invitrogen, 00-4958-02) and stored at 4 °C. Unfixed tissue. To preserve the
sensitive antigen recognized by HAE-4 for certain experiments, unfixed tissue sections were
prepared. Unfixed mouse brain sections. Immediately after transcardial perfusion and brain
extraction, brain hemispheres were snap-frozen in 2-methylbutane (Sigma-Aldrich, 320404) for
1 min before stored at –80 °C. Brains were then sectioned on a Leica CM 1950 cryostat at 20
µm, mounted on Superfrost Plus Microscope Slides (Fisher Scientific), and stored at –20 °C until
use.
ELISA for tissue lysate. Dissected posterior cortices were sequentially homogenized in chilled
PBS containing protease inhibitors and 5 M guanidine-HCL buffer (pH 8.0) using magnetic
beads (Next Advance, Bullet Blender Storm 24). Isolated vessel pellets were sonicated at 50%
amplitude for 1 min total (1 s on, 1 s off) in 5 M guanidine-HCL solution. ELISAs were
performed at room temperature unless otherwise stated. All antibodies were made in-house. The
capture antibody for Aβ40 was anti-Aβ35-40 HJ2 and for Aβ42 was anti-Aβ37-42 HJ7.4. The
detection antibody for Aβ40 and Aβ42 was biotinylated anti-Aβ13-18 HJ5.1B. Aβ were performed
as previously described and collected using Gen5 software version 1.11 with Synergy 2 (BioTek)
(154). Samples were loaded in duplicates, averaged per mouse for a biological replicate. ELISA
data were normalized to brain weight.
ELISA for recombinant APOE binding. Recombinant APOE (Leinco Technologies) was
coated to half-area 96-well plates at 0.5 μg/ml in PBS overnight at 4°C (25 μl/well). After 3
washes with PBS, the wells were blocked with 1% BSA-PBS for 1 hour at room temperature
with shaking at 500 rpm. The blocked wells were washed once with PBS and subsequently load-
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ed with HAE antibodies at serial concentrations (starting at 300 nM with 3-fold dilutions
thereafter). Bound HAE antibodies were detected with HRP-labeled goat anti–mouse IgG
(catalog 115-035-003, Jackson ImmunoResearch Laboratories) and visualized with
tetramethylbenzidine (TMB) substrate at OD450 (reaction stopped with 4N H2 SO4) or OD650
(reaction stopped with BioFX stop solution, Surmodics). For experiments where APOE
aggregation was first induced by heating, recombinant apoE4 at a concentration of 1 mg/ml was
first heated at 40°C for 24 hours and then coated directly to ELISA plates at 0.5 μg/ml. To
normalize the amount of APOE coated to the ELISA plates from the supernatant and pellet
fractions after heating and ultracentrifugation, the relative amounts of APOE were first assessed
by SDS-PAGE followed by a Coomassie blue stain. Heat-induced apoE4 aggregates were
denatured in 1% SDS or 4 M guanidine-HCl at 95°C for 10 minutes and then diluted to 0.5
μg/ml in PBS for coating onto ELISA plates. After overnight incubation at 4°C, the wells were
washed 3 times with PBS to remove any residual SDS or guanidine-HCl. ELISA experiments
with heated APOE used HAE antibodies starting at 100 nM with 5-fold dilutions thereafter.
ELISA for plasma APOE binding. Antibodies were coated at 5 μg/ml in half-well ELISA
plates overnight at 4°C. Plates were washed with PBS and blocked in 4% milk-PBS for 2 hours.
Mouse plasma was serially diluted 2-fold (starting at 10×) in 5% BSA-PBS and incubated on the
blocked plates for 3 hours at room temperature and shaken at 500 rpm. Plates were next washed
extensively in PBS and the captured APOE was detected with polyclonal goat anti–APOE
(catalog 178479, Millipore). Anti–goat HRP (catalog 705-035-147, Jackson ImmunoResearch
Laboratories) and TMB were used as the detection secondary antibody and chromogenic reagent,
respectively. Reactions were stopped with BioFX stop solution and plates were read at OD650.
Replicate assays were performed and data from 1 experiment in duplicate are shown.
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Preparation and injection of AAV2/8 vectors expressing control antibody and HAE
antibodies. The variable regions of heavy and light chain cDNA sequences of control IgG,
HAE-1, and HAE-4 were cloned from hybridoma cells. The single open reading frame (ORF) of
the heavy chain, Furin cleavage site, P2A, and the light chain was assembled by polymerase
chain reaction. All antibody subtypes were switched to mouse IgG2ab. The assembled single
ORF was inserted into AAV-expressing vector (serotype 2) with a chicken β actin promoter. The
D265A mutation on the CH2 region was generated by QuikChange (Agilent Technologies) sitedirected mutagenesis. AAV vectors were prepared at Hope Center Viral Vector Core with
serotype 8 helper vectors. On P0, APPPS1-21/APOE4 mice (mixed sexual phenotype, n = 17–
25/group) received a bilateral i.c.v. injection of 2 μl AAV vector (1.0 × 1013 vg/ml). The mice
were sacrificed at 3.5 months of age. After perfusion with PBS, one brain hemisphere was
immersion fixed in 4% paraformaldehyde for further histological analysis and the other
hemisphere was dissected for further biochemical analysis. For histology, the brains were
sectioned at 50 μm on a freezing sliding micro- tome. The Aβ plaques were stained with anti–Aβ
HJ3.4 and the fibril- lar plaques were stained using X-34. The cortices were sequentially
extracted using PBS and 5 M guanidine, and Aβ40 and Aβ42 were measured by ELISA. The
concentration of antibodies in the PBS fraction was also measured by ELISA.
Statistical analysis. GraphPad Prism was used to perform all statistical analyses. Data are
presented as mean ± SEM. No other statistical comparisons were significant unless otherwise
noted. Two-tailed Student’s t-test was used to assess significance between two groups. One-way
ANOVA was used to determine statistical significance between three or more groups, followed
by Tukey’s t-test unless otherwise specified.
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2.4 Results
2.4.1 Characterization of anti-human APOE antibodies binding to APOE in vitro
We generated a series of novel anti-human APOE monoclonal antibodies (HAE) against
human APOE4 and characterized their binding profile to the three main isoforms of recombinant
human APOE particles. Whereas HAE-1 (IgG1) selectively recognized APOE4 (Figure 2.1A),
HAE-2 (IgG2ab) and HAE-3 (IgG2ab) had appreciable binding to all three isoforms of
recombinant APOE (Figure 2.1B, C). HAE-4 (IgG2ab) recognized both APOE3 and APOE4
(Figure 2.1D). Preincubation of recombinant APOE at 40 °C generated aggregated APOE
(Figure 2.1E–G), which was isolated from the pellet fraction after ultracentrifugation (Figure
2.1F). While HAE-2 bound to both untreated and heat-treated APOE, HAE-1 and HAE-4
preferentially recognized the heat-treated, aggregated conformation of APOE4 only or APOE3
and APOE4, respectively (Figure 2.1E, G).
Native APOE particles produced in the brain and periphery are generally lipidated (44).
To characterize the binding properties of HAEs to a physiological, native form of APOE, we
collected plasma containing APOE that is mostly lipidated from APOE knockout (KO), APOE2,
APOE3, and APOE4 mice. To minimize nonspecific binding in our assay, we used chimeric
HAEs with mouse variable regions fused to human constant regions. All three isoforms of
lipidated APOE were captured by HAE-2 (Figure 2.2A) but not by HAE-4 (Figure 2.2B).
Furthermore, pharmacokinetic experiments demonstrated that HAE-2 and HAE-3 injected into
APOE4 mice (10 mg/kg, i.p) were rapidly cleared from the plasma within 4 hours whereas HAE4 was present in the plasma 14 days after injection at levels similar to the control IgG antibody
(published, data not shown). Combined, these results suggest that HAE-2 and HAE-3 recognized
both plasma-derived, lipidated APOE and recombinant, unlipidated APOE, whereas HAE-1 and
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HAE-4 preferentially recognized poorly lipidated, aggregated APOE3 and/or APOE4. The
different binding preference of these antibodies may influence efficacy of amyloid removal,
which we evaluated in subsequent experiments.

2.4.2 Efficacy of APOE antibodies on parenchymal Aβ
To assess the efficacy of APOE antibodies in preventing Aβ plaque deposition, we
peripherally administered HAEs to a mouse model with parenchymal plaque pathology
expressing human APOE4 (APPPS1-21/APOE4+/+ or APP/E4) before plaque onset at 2 months
of age. APP/E4 mice were treated weekly for 6 weeks (n = 10-13/group, females, 50 mg/kg, i.p.)
with HAEs or a control antibody. Mice were assessed at 3.5 months of age. Because HAE-2 was
similar in properties to HAE-3, we tested only HAE-3, which did not alter Aβ plaque load after a
6-week treatment (published, data not shown). These results were supported by
pharmacokinetics data demonstrating rapid clearance of HAE-3 upon target engagement of
peripheral, lipidated APOE (published, data not shown). We were surprised, however, that HAE1 which binds unlipidated, aggregated APOE4 in vitro, did not reduce Aβ plaque pathology
(Figure 2.3A–E). HAE-4 which preferentially recognizes unlipidated, aggregated APOE3 and
APOE4 in vitro, significantly reduced Aβ plaque load in APP/E4 mice by Aβ immunostaining
compared to control antibody (Figure 2.3A, B). Furthermore, HAE-4 significantly lowered
insoluble Aβ40 and Aβ42 in the guanidine fraction of posterior cerebral cortex by ~40% (Figure
2.3D, E). Given the strong effect of HAE-4 in removing plaques, we expected to detect a
reduction in APOE levels in the brain, where APOE is found abundantly. To our surprise, HAE4 did not alter APOE concentrations in either the brain or plasma by ELISA (Figure 2.4). These
findings suggest that perhaps HAE-4 recognizes a non-native form of apoE that is not found in
brain or plasma. To visualize the binding of HAE-4 to APOE in the brain, we administered
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antibodies to 6-month-old APP/E4 mice with high plaque burden. At 48 hours after treatment,
HAE-4 bypassed the blood-brain barrier (BBB) and densely-stained puncta throughout the
cerebral cortex, resembling Aβ plaques that typically develop in this mouse model (published,
data not shown). Together, these experiments suggest that HAE-4 recognizes a small component
of APOE that is poorly-lipidated and localized to the dense core of Aβ plaques.

2.4.3 Fc effector function is necessary for microglial-mediated reduction of Aβ plaques.
Many Aβ antibodies have been previously shown to exert their effects through activation
of microglia via binding to Fcγ receptors (FcγR) RI, RIII, and RIV (155). To determine whether
HAEs elicited microglial activation, we acutely treated 4-month-old APP/E4 with HAE-1
(IgG1), HAE-4 (IgG2ab), or a control antibody (IgG2ab) (4 injections every 3 days at 50 mg/kg,
i.p.). Mouse IgG2a antibodies elicit microglial reaction in response to target engagement
activating FcγR whereas IgG1 do not (156, 157). As expected, HAE-4 demonstrated a 40%
increase in CD45+ microglia staining coverage (a marker of reactive microglia) in cortex whereas
HAE-1 did not increase a CD45+ microglial response (Figure 2.5A, B). These results suggest
that microglial activation may be necessary for the reduction of Aβ plaques. To determine
whether Fc effector function was necessary for the reduction of Aβ plaques, we ablated the Fc
effector function of HAE-1 and HAE-4 with a D265A (Δ) mutation which eliminated receptor
binding (158). For these experiments, we generated adeno-associated viruses serotype 2 with a
capsid of type 8 (AAV2/8) to secrete full-length HAE-1 (IgG2ab for these experiments) and
HAE-4 (IgG2ab). For all previous experiments, HAE-1 was the IgG1 isotype, which had low
affinity for FcγR on microglia. On postnatal day 0 (P0), APP/E4 mice received bilateral
intracerebroventricular injection of PBS, AAV-IgG2ab, AAV-HAE-1, AAV-HAE-4, AAVHAE-1Δ, or AAV-HAE-4Δ. Mice were assessed at 3.5-months-of-age. Compared to the control
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group, both AAV-HAE-1 and AAV-HAE-4 significantly reduced Aβ plaque staining, fibrillar
staining, and Aβ protein concentrations (Figure 2.6A–D). However, ablating the Fc effector
function of both HAE-1 and HAE-4 resulted in no reductions of Aβ plaques (Figure 2.6A–D).
These results strongly suggest that the reduction in Aβ plaques by HAE-4 is driven by FcγRmediated mechanism via microglial recruitment and phagocytosis.

2.5 Discussion
The search for disease-modifying agents to prevent or cure AD has been ongoing for
decades without yet an approved treatment. Many therapeutic strategies that have entered clinical
trials were developed to target Aβ production or clearance including BACE inhibitors, γsecretase inhibitors, active and passive immunotherapy (159). Unfortunately, many of these
therapeutics have been discontinued with numerous reasons including lack of efficacy, adverse
effects, and treatment administered too late in the disease process. Given the strong influence of
APOE on Aβ deposition, there has been recent excitement in APOE-targeting approaches,
including transcriptionally modulating the expression of APOE with antisense oligonucleotides
(79) and lipidation with compounds such as bexarotene, an retinoid X receptor agonist (78). In
our current studies, we employ an APOE-directed therapeutic strategy to indirectly facilitate the
reduction of Aβ plaques. We conducted this study aimed to address the following question: [1]
What is the target of these anti-human APOE antibodies? [2] Do anti-human APOE antibodies
reduce Aβ plaques in a mouse model of amyloidosis? [3] What are the underlying mechanisms
of the APOE antibodies?
In this study, we generated a series of anti-human APOE antibodies with varying binding
properties. Each antibody has unique characteristics, including preference for [1] APOE isoform,
[2] lipidation state, [3] APOE aggregation, as well as antibody [4] isotype and [5] Fc effector
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function (Figure 2.7). Specific combinations of these properties determined whether the APOE
antibody would be efficacious in reducing Aβ. Only one APOE antibody was effective when
administered peripherally: HAE-4. HAE-4 preferentially recognized poorly-lipidated, aggregated
APOE3 and APOE4 but not lipidated APOE. HAE-4 was produced with the mouse IgG2a
isotype, which allowed for binding to the activating IgG Fcγ receptor IV for microglial activation
(160). HAE-1, which shared similar properties to HAE-4 but harbored an IgG1 backbone, had
lower binding affinity to activating FcγRIV which was insufficient for Aβ plaques clearance in
our study. However, when HAE-1 was switched to an IgG2a serotype via AAV expression,
HAE-1 significantly reduced Aβ deposition, suggesting binding of activating Fcγ receptors were
necessary to reduce plaques for HAE-1. Replacement of aspartic acid by alanine at position 265
(D265A) abolished binding of IgG2a to all FcγRs and consequently minimized microglial
activation (158), rendering both HAE-1 and HAE-4 inefficacious in reducing Aβ pathology.
These results imply that effector function was indispensable for HAE-mediated Aβ reducing
effects. HAE-2 and HAE-3, which shared similar properties, recognized all three isoforms of
lipidated and unlipidated human APOE. Despite produced on the IgG2a subclass, HAE-2 and
HAE-3 did not reduce Aβ deposition, likely because of target engagement of lipidated APOE in
the periphery. This hypothesis is supported by pharmacokinetics data showing that HAE-2 and
HAE-3 were cleared within four hours of peripheral injection, whereas HAE-1 and HAE-4 were
still detectable in the plasma at 14 days. With minimal target engagement in the periphery and
extended half-life, it is possible that a reservoir of antibody was retained for longer in the
periphery to allow for more antibody to enter the brain. Previously, our group discovered that an
anti-mouse APOE antibody HJ6.3 reduced Aβ plaques with peripheral administration, but
limited mechanistic studies were performed to understand the mechanism of action (152, 153). In
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hindsight, this APOE antibody targeting mouse APOE likely also recognized poorly-lipidated
APOE because it had minimal effects on lowering APOE levels in the brain and plasma.
Combined with our current study, our findings imply that the effects of APOE antibodies were
not mediated by lowering total APOE levels. Taken together, these results suggested that an
APOE antibody with intact effector function provided optimal therapeutic activity when engaged
with poorly-lipidated APOE found in Aβ plaques.
A major adverse effect of current Aβ antibodies targeting aggregated Aβ are vascular
complications that induce edema and hemorrhagic events. In the previous study assessing the
efficacy of anti-mouse APOE antibody HJ6.3 in 11-month-old APPswe/PS1ΔE9 mice, there was
no increased microhemorrhage severity (153). These results are not surprising given that at this
age, APPswe/PS1ΔE9 mice have minimal cerebral amyloid angiopathy (CAA), which contain
vascular Aβ deposits in the brain that are necessary to elicit a vascular response. In the current
study, APP/E4 mice at 3.5-months-of-age have virtually no CAA, thus we did not assess for
CAA-related microhemorrhages. To determine whether anti-human APOE antibody HAE-4
would elicit adverse vascular effects, future studies using a mouse model with sufficient CAA
and an Aβ antibody known to cause microhemorrhages are required. These experiments would
help assess the safety of APOE-targeting strategies and would bolster the usage of APOE
immunotherapy as a treatment for AD.
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2.6 Figures and tables

Figure 2.1 | Binding profile of APOE antibodies to recombinant, nonlipidated APOE
A–D, 96-well plates coated with recombinant APOE2, APOE3, or APOE4 before incubation
with increasing concentration of anti-APOE antibodies. E–F, Binding of APOE antibodies to
heat-treated (aggregated) recombinant APOE4 (E) and to the pellet fraction (P) (F) or to the nonaggregated supernatant fraction (S) after heat-treatment and ultracentrifugation (F, G). Sup =
Supernatant. Pel = Pellet. Supernatant/pellet fraction of APOE4 incubated at 40 °C for 24 hours.

Figure 2.2 | Affinity of APOE antibodies for plasma-derived, lipidated APOE
A, B, Plasma from APOE KO, APOE2, APOE3, and APOE4 mice coated on a 96-well plate and
captured with an increasing concentration of APOE antibodies. Chi-HAE: Chimeric-HAE.
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Figure 2.3 | Reduction of Aβ plaques after chronic intraperitoneal APOE antibody
treatment
2-month-old APPPS1-21/APOE4 treated weekly with antibodies for six weeks were assessed at
3.5-months-of-age. A–C, Representative images of Aβ and X34 staining (A) with quantification
of percent area covered (B, C). Insoluble Aβ40 (D) and Aβ42 (E) protein concentrations from
posterior cortex assessed by ELISA and normalized to cortical weight. Scale bar = 1 mm. Data
expressed as mean ± SEM, one-way ANOVA with Tukey post-hoc test. *p<0.05, **p<0.01.
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Figure 2.4 | Anti-APOE antibody treatment did not alter cortical and plasma APOE levels
A–C, APOE concentrations assessed by ELISA in PBS-soluble fraction of cortex (A), guanidinesoluble (“insoluble”) fraction of cortex (B), and plasma (C). D, Plasma Aβ40 protein
concentration determined by ELISA. Data expressed as mean ± SEM, one-way ANOVA with
Tukey post-hoc test.
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Figure 2.5 | Acute treatment with HAE-4 induces activation of microglia
Assessment of 4-month-old APPPS1-21/APOE4 mice treated for 4 days, every 3 days (i.p., 50
mg/kg, N=8–9/group). A, B, Brain sections stained for CD45+ activated microglia and X34+
fibrillar plaques (A) with quantification of CD45+ microglia normalized to amyloid load (B).
Scale bar = 1mm. Data expressed as mean ± SEM, one-way ANOVA with Tukey post-hoc test.
*p<0.05.
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Figure 2.6 | Reduction of plaques by HAE-4 requires effector function
APPPS1-21/APOE4 mice injected at P0 with AAV 2/8 expressing full-length antibodies, either
with or without a D265A mutation in the Fc domain (HAEΔ) bilaterally into the ventricles. A, B,
3.5-month-old mouse brain sections stained with pan-Aβ antibody HJ3.4 (A) or X34 for amyloid
(B). C, D, Insoluble Aβ40 (C) and Aβ42 (D) protein concentrations from posterior cortex assessed
by ELISA and normalized to cortical weight. Data expressed as mean ± SEM, one-way ANOVA
with Tukey post-hoc test. *p<0.05.
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Figure 2.7 | Summary of HAE properties
Binding properties of different HAEs to varying APOE isoforms, lipidation status, aggregation,
and treatment effects on Aβ and microglia. Green circle: recombinant APOE2. Yellow circle:
recombinant APOE3. Red circle: recombinant APOE4.
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Chapter 3:
APOE4 immunotherapy reduces vascular
amyloid pathology without inducing
microhemorrhages
This chapter is partially adapted from the following manuscript
M. Xiong, H. Jiang, J. R. Serrano, E. R. Gonzales, C. Wang, M. Gratuze, R. Hoyle, N. Bien-Ly,
A. P. Silverman, P. M. Sullivan, R.J. Watts, J.D. Ulrich, G.J. Zipfel, D. M. Holtzman, APOE
immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving
cerebrovascular function. Sci. Transl. Med. 13, eabd7522 (2021).
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3.1 Summary
Monoclonal antibodies against Aβ that reduce amyloid plaques in human amyloid
precursor protein (APP) transgenic mice can also result in cerebral amyloid angiopathy (CAA)
associated microhemorrhages. When such anti-Aβ antibodies have moved into Alzheimer
disease (AD) clinical trials, they have resulted in side effects such as amyloid-related imaging
abnormalities (ARIA). Microhemorrhages associated with CAA are potentially exacerbated by
anti-Aβ antibodies that bind to fibrillar Aβ in CAA, which results in local microglial activation
and damage to the vessel wall. Our lab generated a series of antibodies against APOE4, the
strongest genetic risk factor for late-onset AD (see Chapter 2) (154). APOE is an apolipoprotein
that is found in Aβ deposits in the parenchyma (amyloid plaques) and vasculature (CAA). One of
our APOE antibodies (HAE-4) reduced parenchymal Aβ plaques by preferentially targeting
poorly-lipidated, aggregated APOE in APP transgenic mice. To compare the effects of this
APOE antibody to an Aβ antibody known to decrease amyloid plaques as well as produce ARIA,
we produced chimeric aducanumab (chi-Adu) harboring mouse Fc and human variable regions.
We generated a mouse model of vascular and parenchymal plaque pathology by crossing
5XFAD mice (line 7031) expressing human APOE4. After two months of weekly antibody
treatments (50 mg/kg, intraperitoneal), HAE-4 significantly decreased fibrillar Aβ deposits
whereas chi-Adu did not. However, chi-Adu increased antibody-associated microhemorrhage
severity whereas HAE-4 was not only well-tolerated, but also improved vasofunction in arteries
laden with CAA. These results suggest that targeting a small but abnormal conformation of
APOE in plaques may safely reduce plaques without eliciting adverse side effects such as ARIA.
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3.2 Introduction
Therapeutic approaches using passive immunotherapy targeting amyloid-β (Aβ) are at the
forefront of disease-modifying strategies to treat Alzheimer Disease (AD). Aβ, which deposits in
the brain parenchyma as amyloid plaques and in cerebrovasculature as cerebral amyloid
angiopathy (CAA), begins to accumulate 15 to 20 years before cognitive impairment due to AD
(10), emphasizing the need for a treatment that is both effective and safe to administer
chronically. One potential impediment for anti–Aβ antibodies that successfully remove amyloid
in the brain is the manifestation of amyloid-related imaging abnormalities (ARIA), an adverse
effect secondary to treatment with anti–Aβ antibodies targeting aggregated Aβ (139, 143, 161).
ARIA manifests in the human brain as edema (ARIA-E) or hemorrhages (ARIA-H) and occurs
more frequently in patients who are APOE ε4 carriers or receiving high doses of Aβ antibody
(162). Some individuals with ARIA become symptomatic with headaches, confusion, and
neuropsychiatric symptoms (162). Although the mechanism for ARIA is unclear, Aβ antibodyinduced microhemorrhages are associated with CAA (163–166). Most, but not all, patients in
recent trials on anti-Aβ antibodies who develop ARIA can ultimately remain on the antibodies
with dose adjustments (167, 168). However, because CAA is almost universally detected in
patients with AD (16), Aβ removal with avoidance of ARIA would be greatly preferable.
Although Aβ is the main constituent of extracellular amyloid plaques, there are other less
abundant constituents including apolipoprotein E (APOE) (68, 169). The APOE4 gene is the
strongest genetic risk factor for late-onset AD and exacerbates the development of Aβ pathology
through several mechanisms, including affecting Aβ aggregation and clearance (50, 170).
Previously, we demonstrated that passive immunotherapy targeting mouse APOE or human
APOE4 reduced Aβ pathology in mice with parenchymal amyloidosis (152–154). Our current
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anti-human APOE antibody of interest (HAE-4) recognizes poorly-lipidated human APOE only
present in amyloid plaques (154).
To recapitulate both the vascular and parenchymal Aβ pathology found in AD human
brains, we utilized an animal model that deposits Aβ mostly in the form of CAA and also in the
brain parenchyma. Our goal was to determine if HAE-4 treatment could decrease CAA
pathology and subsequently improve vessel function without eliciting adverse effects. We
compared the treatment effects of HAE-4 against chimeric aducanumab (chi-Adu), a monoclonal
antibody with the ability to remove plaques by binding oligomeric/fibrillar Aβ and induced
ARIA in clinical trials (143). We also investigated the mechanisms of action of an APOE
antibody and an Aβ antibody, which are largely unknown particularly in the context of CAA.

3.3 Experimental methods
Animals. All animal procedures and protocols were approved by the Animal Studies Committee
at Washington University School of Medicine. 5XFAD mice (line Tg7031) were originally on a
C57/B6 X SJL background (a gift from Dr. Robert Vassar at Northwestern University) (171).
Human APOE4+/+ knock-in mice on a C57BL/6 J background express human APOE4 under
control of the native murine Apoe gene regulatory sequences (63). 5XFAD and APOE4+/+ mice
were crossed to generate 5XFAD / APOE4+/+ (5XE4) mice (172). All subsequent mice were bred
on a C57/BL6 J background for at least 10 generations and each study utilized mice bred on the
same generation. Age-matched APOE4+/+ littermates negative for the 5XFAD transgene were
used as non-transgenic, wildtype controls. Male 5XFAD mice (line Tg6799) on a C57/B6 X SJL
background were purchased from The Jackson Laboratory (34840-JAX). All mice were housed
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in standard cages under pathogen-free conditions on a normal 12-h light/dark cycle with ad
libitum access to food.
Antibody generation. The generation of murine HAE-4 and control IgG was previously
described in Chapter 2. The control IgG recognizes human PLD3 sequences not found in mice.
HAE-4 and control IgG are IgG2ab isotype. The protein sequences for chimeric aducanumab
(chi-Adu) variable heavy chain and light chain (WO 2016/087944) were codon-optimized,
generated as double-stranded DNA fragments (Integrated DNA Technologies), and cloned into
expression vectors with mouse IgG2ab and mouse Kappa constant regions, respectively.
Recombinant antibody was produced by transient co-transfection of heavy and light chain
vectors in Expi293 cells (Thermo Fisher) followed by purification by Protein G chromatography.
Immunohistochemistry, immunofluorescence, and quantification. Refer to Chapter for
detailed methods. If X34 or Thioflavin S (ThioS) was the only stain, images were captured on
the Nanozoomer slide scanner. All other images were captured on the Nikon A1R+ confocal
microscope. Human staining. All participants gave prospective pre-mortem written consent for
their brains to be banked and used for research. Unfixed human cortical tissue sections (50 µm)
were pre-mounted on slides and treated with 50 mM sodium citrate buffer in 0.05% Tween (pH
6.0) at 95 °C for 30 min. Staining proceeded as previously described. Images of unfixed mouse
and human brain tissue were captured using the Cytation 5 imager at 4× magnification with
image stitching (BioTek). Isolated vessels. 50 µL of 1 mL resuspended isolated
cerebrovasculature in 0.5% BSA in HBSS were dried on slides. Prior to staining, slides with
unfixed tissue or vessels were returned to room temperature and promptly fixed in chilled 100%
methanol for 10 min. Tissue staining proceeded as described above.
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Microhemorrhage analysis. 20–21 equally spaced sections (bregma 2.9 to –3.5) were premounted on glass slides before staining. Slides were first stained for vascular bleeds marked by
hemosiderin deposits by incubating in 2% potassium ferrocyanide (Sigma-Aldrich, P3289) in 2%
hydrochloric acid for 30 min. Next, slides were immersed for 10 min in 0.025% Thioflavin S
(ThioS, Sigma-Aldrich, T1892) prepared in 50% ethanol in TBS, and subsequently rinsed in
50% ethanol in TBS (2 X 10 min) and TBS (3 X 5 min) before coverslipped with FluoromountG. Slides were imaged with Nanozoomer slide scanner at 40x. Microhemorrhages were manually
traced using NDP.View2 software for calculations of microhemorrhage number per brain section
and size per microhemorrhage. Analyses and tracings were completed while blind to treatment.
Confocal imaging and analyses. For each mouse, 3 z-stack images were captured on the Nikon
A1R+ confocal microscope using 20x or 60x oil objective at 1024 × 1024 pixel resolution with a
z-step size of 1.1 μm at 32 μm thickness. The same settings were used throughout an experiment.
Acquired z-stack images were imported to Fiji software (ImageJ) and slices were merged into
one stack (stack/Z projection) for each channel. Images were processed and analyzed after
blinding to treatment.
Cerebrovasculature isolation. As previously described with minor modifications (173),
immediately after transcardial perfusion, the forebrain was dissected and homogenized in a glass
Dounce homogenizer (Kimble, 885300-0002) containing 20% w/v chilled vessel buffer (Hanks'
Balanced Salt Solution, HBSS, HyClone, SH30268.02; 15 mM HEPES, Gibco, 15630080; 1 mM
sodium pyruvate, Gibco, 11360070; 0.5% Bovine serum albumin, BSA, Fisher Scientific,
50550390; 1% dextran, Sigma-Aldrich, D8821). Next, vessels in vessel buffer were mixed with
an equal volume of 31% dextran in water and centrifuged at 8000 x g for 30 min at 4 °C, which
resulted in separation into three layers: vessel-free parenchyma (top), vessel-dextran solution
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with myelin/debris (middle), and vascular pellet (bottom). The parenchyma and myelin were
removed and stored at –20 °C. To clean the vessels, three washes were performed using 0.5%
BSA in HBSS. The well-resuspended vessel solution was further purified by passing over a 70
µm nylon mesh strainer (Miltenyi Biotec, 130-098-462). Vessels were washed with 0.5% BSA in
HBSS, centrifuged at 20,627 x g for 2 min at 4 °C in PBS, and stored at –80 °C. Vessels isolated
from one forebrain of each mouse was considered an individual biological replica.
ELISA. Refer to Chapter 2 for detailed methods. Brain lysate. Dissected posterior cortices were
sequentially homogenized in chilled PBS containing protease inhibitors and 5 M guanidine-HCL
buffer (pH 8.0) using magnetic beads (Next Advance, Bullet Blender Storm 24). Isolated vessels.
Vessel pellets were sonicated at 50% amplitude for 1 min total (1 s on, 1 s off) in 5 M guanidineHCL solution. All samples were loaded in duplicates, averaged per mouse for a biological
replicate. ELISA data were normalized to total protein concentration using the Pierce Micro
BCA Protein Assay Kit (Thermo Scientific, 23235) following manufacturer’s instructions.
Live vascular imaging. Cerebrovascular function measurements were conducted as previously
described(174) with a few modifications. Experiments were performed one week after the last
i.p. injection. One femoral artery was cannulated for blood gases sampling (Nova Biomedical,
BioProfile pHOx Analyzer) and a tracheostomy was performed under isoflurane (4% induction,
1.5% maintenance) for mechanical ventilation (Harvard Apparatus, MiniVent Ventilator)
supplemented with 0.5% flow of 100% O2. Fluorescein-dextran (Life Technologies, D1823, 150
uL at 12.5 mg/mL) was injected retro-orbitally for visualization of pial vessels. Mice were
weaned off isoflurane (a vasodilator) and anesthetized with pentobarbital which does not dilate
vessels (i.p., 1.35 mL/kg from 50 mg/mL stock solution for first dose, 0.70 mL/kg for subsequent
doses). For the craniotomy, mice were secured to a custom-built stereotaxic device (Instrument
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Machine Shop at Washington University School of Medicine) and the leptomeninges were
exposed by gently removing the right parietal bone (4 mm in diameter) after drilling. A dental
cement ring (Parkell, S380, 10 mm in diameter) surrounding the craniotomy was placed on the
skull and filled with artificial cerebrospinal fluid (aCSF, in mM: 125 NaCl, 26 NaHCO3, 1.25
NaH2PO4, 2.5 KCl, 1 MgCl2, 1 CaCl2, and 25 mM glucose). To label fibrillar CAA, X34 dye
was topically applied for 20 min to the cortical craniotomy. Next, the stage with the head-fixed
mouse was secured to the Nikon Eclipse 600ME digital video microscopy system (Nikon
Instruments Inc.). One vessel from a ramification of the middle cerebral artery (~20 µm in
diameter) was imaged for the experiment if it contained both CAA-laden and CAA-free
segments. Images were captured at 20x with water-immersion lenses at 1024 x 1024 pixels using
MetaMorph imaging software version 7.10.2 (Molecular Devices). Two drugs were randomly
assigned and topically applied to the window for 5 min: endothelium−dependent vasodilator
acetylcholine (ACH; Sigma-Aldrich, A2661, 10 μM) or vascular smooth muscle cell−dependent
vasodilator S−Nitroso−N−acetyl−penicillamine (SNAP; Sigma-Aldrich, N3398, 50 μM). To
induce hypercapnia, mice were ventilated with 50% less volume and strokes per minute for 5
min. Images were captured at baseline and 5 min after each condition. After drug applications,
aCSF was continuously infused for at least 30 min to allow vessel diameters to return to baseline.
Baseline blood samples were collected at the start of the experiment and at the end of induced
hypercapnia. Images were imported into Fiji (ImageJ) and the diameters of 6–8 ~30 µm vessel
segments in length were measured with ObjectJ software plug-in version 1.04q. Data were
calculated as percent vasodilatory change from baseline and grouped by amount of CAA
coverage in the vessel segment. At least two vessel segments with less or more than 50% CAA

47

coverage were averaged per mouse. Vessel segments from one mouse were averaged and
analyzed as an individual biological replica.
Statistical analysis. GraphPad Prism 8.0.2 was used to perform all statistical analyses. Data are
presented as mean ± SEM. No other statistical comparisons were significant unless otherwise
noted. Gaussian distribution of data was first checked with the Anderson-Darling, D’Agostino &
Pearson, and Shapiro–Wilk normality tests. Statistical significance between two groups with
normally distributed data were calculated using a student’s t-test (two-tailed). For three or more
groups, one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test or Dunnett’s
post hoc test was used to determine statistical significance. If data were not normally distributed,
a Kruskal-Wallis test with Dunn’s multiple comparisons was performed instead. In studies with
multiple groups and two or more factors, a two-way ANOVA with Tukey’s post hoc test was
calculated for statistical significance.

3.4 Results
3.4.1 Anti-human APOE antibody HAE-4 reduces CAA and parenchymal Aβ plaques
First, we validated the efficacy of chi-Adu containing the human variable heavy and light
chain sequences of Aducanumab and a mouse immunoglobulin G (IgG) 2ab Fc domain. Chi-Adu
significantly reduced Aβ plaques compared to control IgG in 3.5-month-old 5XFAD (line 6799)
mice, which develop aggressive Aβ parenchymal plaques beginning at 2-months-of-age (Figure
3.1). For all further experiments, we used 5XFAD (line 7031) transgenic mice expressing human
APOE4+/+ (5XE4) that exhibit robust CAA starting at 6-months-of-age (172). To assess the
efficacy of HAE-4 compared to chi-Adu, we chronically treated 5XE4 mice after CAA and
plaque onset from 8- to 10-months-of-age for 8 weeks with weekly intraperitoneal (i.p.)
injections at 50 mg/kg (Figure 3.2A). HAE-4 significantly reduced Aβ staining (HJ3.4B+;
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Figure 3.2B–E) and fibrillar (Thioflavin-S, ThioS+; Figure 3.2F–I) parenchymal and vascular
plaques compared to control IgG. HAE-4 reduced both small and large parenchymal Aβ plaques
(Figure 3.3). There were no sex-dependent differences in Aβ plaque load in response to antibody
administrations (Figure 3.4A–F), but there was a significant treatment effect (Figure3.43A–E,).
We also assessed the Aβ concentrations from guanidine-soluble (“insoluble”) fractions of bulk
cortical or forebrain vasculature extracts (Figure 3.2J–O). HAE-4 significantly reduced
insoluble bulk cortical Aβ42 (Figure 3.2K) and insoluble vascular Aβ40 and Aβ42 (Figure 3.2N,
O) compared to chi-Adu but not compared to control IgG (Figure 3.2K: P = 0.09; Figure 3.2N,
O: P = 0.08). These data suggest that HAE-4 not only reduced parenchymal plaques consistent
with our previous findings (154), but also decreased CAA and exhibited higher efficacy
compared to chi-Adu in a mouse model with prominent CAA.
3.4.2 Chi-Adu but not HAE-4 exacerbates CAA-related microhemorrhages
The pathogenic mechanism underlying ARIA is unclear. One hypothesis is that focal,
prolonged inflammation resulting from Aβ antibodies targeting of CAA impairs vascular
integrity, leading to microhemorrhages or ARIA (166, 175). Given that HAE-4 is selective for
nonlipidated APOE, a small component of the material in ThioS+ or X34+ dense core plaques
and CAA, we hypothesized that HAE-4 would be involved in microglial-mediated Aβ removal
but would induce less prolonged inflammation compared to chi-Adu. Whereas HAE-4 favors
dense core fibrillar plaques, chi-Adu binds abundantly to both diffuse and fibrillar plaques in
tissue from 5XE4 mice and human CAA and AD individuals (Figure 3.5, Table 3.1), which may
potentially overstimulate an immune response that is detrimental to the vasculature.
To assess for CAA-linked microhemorrhages, we stained brains from antibody-treated
mice with Perl’s Prussian blue dye, which identifies hemosiderin deposits indicative of prior
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hemorrhages (Figure 3.6A). After two months of treatment, HAE-4 did not produce additional
antibody-induced microhemorrhages relative to control IgG. However, chi-Adu exacerbated
microhemorrhage severity by increasing the frequency of varying sizes of microbleeds (Figure
3.6B–D), recapitulating findings of increased ARIA after aducanumab treatment in recent
clinical trials (143). We also tested another anti-Aβ antibody “HJ3.4” that recognizes N-terminal
Aβ (IgG2b), which was previously shown to not significantly reduce guanidine-soluble Aβ40 and
Aβ42 in a mouse model of parenchymal Aβ plaques (154). In this study, we reproduced these
findings suggesting no significant reductions of fibrillar plaques with HJ3.4 treatment (Figure
3.7A) but also no exacerbation of microhemorrhages (Figure3.7B), suggesting that Aβ
antibodies that bind different species of plaques have different mechanisms in eliciting a
microhemorrhagic response. No sex differences in microhemorrhage incidence were observed
among treatment groups (Figure 3.4G, H).
3.4.3 HAE-4 restores vascular function to CAA-laden pial arteries
Chronic treatment with HAE-4 reduced parenchymal Aβ plaques and CAA without
vascular complications. These results prompted us to ask whether HAE-4-mediated CAA
reduction could provide a favorable milieu to rescue cerebrovasculature dysfunction which is
caused by CAA (176). In 12-month-old 5XE4 mice treated with control IgG, HAE-4, or chi-Adu
for 8 weeks (50 mg/kg, i.p., weekly), we assessed vascular reactivity to vasodilatory
pharmacological and physiological agents in leptomeningeal arteries (Figure 3.8A). We
evaluated vasodilation in vessels with comparable diameters and amount of CAA to dissociate
the antibody treatment effect on vasodilation from amyloid removal (Figure 3.9). Application of
the endothelium-dependent vasodilator acetylcholine (ACH) resulted in significantly improved
responses in vessel segments with lower (<50%) and higher (>50%) CAA burden after HAE-4
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treatment, nearly restoring vasoreactivity to those of CAA-free, non-transgenic controls (Figure
3.8B, C). Vessels with less CAA were expected to retain more function in response to stimuli
(176). S-nitro-N-acetyl-DL-penicillamine (SNAP), a nitric oxide donor that directly relaxes
smooth muscle cells, also evoked enhanced vascular tone after HAE-4 treatment (Figure 3.8D, P
= 0.047 treatment interaction by two-way ANOVA). CO2 challenge using hypercapnia in HAE4-treated mice also resulted in improved vasodilation compared to control IgG in vessels with
lower CAA burden (Figure 3.8E). Blood gases collected at normocapnia (baseline) and
hypercapnia were not different between groups (Table 3.2). These results concur with reports of
improved vascular function associated with vascular Aβ removal (174). Together, we
demonstrated that HAE-4, in addition to not exacerbating CAA-related microhemorrhages, also
protected vessel integrity by restoring function to certain cells of the neurovascular unit that are
often compromised in CAA (122, 177).

3.4.4 Characterization of HAE-4 binding to secreted APOE in vitro and in vivo
Our data thus far have demonstrated that HAE-4 can recognize APOE found in the core
of parenchymal plaques and CAA to reduce plaque pathology both before and after the onset of
amyloid pathology. However, whether this form of APOE is found outside of the context of Aβ
plaques remains undetermined. Previously, we have shown that APOE particles produced by
microglia are smaller compared to those produced by astrocytes (178), which may suggest that
microglial-secreted APOE are less lipidated than APOE secreted by astrocytes which are high
density lipoprotein (HDL)-like. APOE4 particles are reported to be less lipidated than APOE3
and APOE2 particles (179, 180). We preliminary tested the binding of HAE-4 to lipidated
APOE2, APOE3, and APOE4 particles derived from immortalized astrocytes compared to
nonlipidated, recombinant APOE2 and APOE4. Previously, HAE-4 recognized recombinant with
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high affinity while demonstrating little to no affinity for APOE2. We reproduced these findings
and also demonstrated that HAE-4 had low affinity for lipidated astrocytic APOE (Figure 3.10).
Future studies will test the binding affinity of HAE-4 to the different isoform of APOE secreted
by other cell populations, including microglia.
Given that HAE-4 does not recognize astrocyte-derived APOE, which is the primary
source of APOE in the CNS, we asked whether poorly-lipidated APOE existed in a context
without amyloid plaques. To address this question, we immunostained for HAE-4 in APOE4+/+
and P301S/APOE4+/+ tau transgenic mice, the latter of which has severe age-dependent taumediated neurodegeneration and tau pathology (62). However, by immunostaining, there was no
detectable poorly-lipidated APOE in either mouse model, suggesting that poorly-lipidated APOE
are predominantly sequestered into Aβ plaques (Figure 3.11). Future studies will assess the
presence of poorly-lipidated APOE in various transgenic mouse models with sensitive
biochemical assays.
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3.5 Discussion
Over the past 25 years, the amyloid hypothesis has gained traction as one of the main
contributors for the pathogenesis of AD. Overwhelming evidence from genetic, pathological, and
biochemical data implicate cerebral Aβ accumulation as the initiator of AD in the long
preclinical phase which is followed by tau pathology in the early clinical phase. Numerous antiAβ antibodies have been developed and engineered to recognize oligomerized/aggregated forms
of Aβ. Some of these antibodies such as aducanumab, gantanerumab, and BAN-2401 can remove
brain amyloid, improve downstream markers of degeneration such as tau, phospho-tau, and
neurofilament light in the cerebrospinal fluid, and possibly slow cognitive decline in clinical
trials. Although promising, these types of Aβ antibodies have all resulted in ARIA, an adverse
effect that occurs in association with CAA resulting in brain edema and hemorrhages. Multiple
theories have been postulated for the pathogenesis of ARIA, but the underlying mechanism is
still unknown. ARIA is exacerbated in patients who are APOE4 carriers or receiving higher Aβ
antibody dosing (162). Because APOE4 is the greatest genetic risk factor for sporadic AD and
CAA and the APOE protein is deposited within Aβ plaques and CAA, various therapeutic
strategies have targeted APOE4 and exhibited success in reducing parenchymal Aβ plaque
burden in mice (see (27) for review). Our lab generated antibodies against human APOE4 (HAE4) to remove Aβ plaques and facilitate Aβ clearance. Here, we aimed to answer the following
questions: [1] Can HAE-4 also reduce CAA, a comorbid neuropathological finding among most
AD patients, by targeting a specific form of APOE after plaque and CAA onset? [2] Does HAE4 exacerbate microhemorrhage severity compared to an Aβ antibody – why or why not?
In this study, we report that HAE-4 has a synergistic effect in reducing CAA and Aβ
parenchymal plaques while neutralizing Aβ-mediated vascular toxicity even after the onset of
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plaque deposition. One discrepancy noted was that the immunostaining and biochemical
measurements of plaque load differed based on the assay employed. One possible explanation is
that different epitopes of the antibodies used in immunostainings and ELISAs led to slightly
different results. The ELISAs performed were specific for Aβ40 and Aβ42. For histology, X34
labeled β-sheet structures and HJ3.4 is an N-terminal anti-Aβ antibody targeting all Aβ species in
addition to Aβ40 and Aβ42. These differences may explain the non-significant trend that we
detected after HAE-4 treatment. It may also be possible that more sequential extractions to
further isolate the guanidine-soluble Aβ40 and Aβ42 by initially introducing a detergent-soluble
buffer may reveal significant reductions. The effect of HAE-4 treatment, which targets insoluble
Aβ, may be masked by the presence of soluble Aβ. Another explanation is that a few more mice
per group may decrease the variability to reach statistical significance, as, the decrease in Aβ42
after HAE-4 treatment is 39%, which is substantial and similar to levels of reduction reported in
Chapter 2.
HAE-4 specifically binds to poorly-lipidated APOE in the core of plaques and
presumably recruits phagocytic microglia. We discover here that this form of APOE is also
found in CAA. Although astrocytes are the predominant producers of lipidated APOE that are
HDL-like in the central nervous system (CNS), the source of poorly-lipidated APOE found
specifically in the core of Aβ plaques is yet to be determined. Recent findings suggest that one
potential cellular source of less-lipidated APOE are microglia, which secrete APOE particles in
vitro that are smaller and thus less-lipidated compared to the larger HDL-like particles produced
by astrocytes (178). In our current in vitro study, HAE-4 has minimal affinity for astrocytesecreted APOE regardless of the APOE isoform, suggesting that HAE-4 binds minimally to
astrocytic APOE and cannot differentiate between the lipidation levels of particles, as particles
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from APOE4 (presumably derived from astrocytes) have been reported to be less lipidated than
particles from APOE3 or APOE2 (179, 180). Furthermore, detection of HAE-4+ poorly-lipidated
APOE is restricted to APP transgenic models at least by immunostaining. Although it is possible
that poorly-lipdated APOE is secreted by microglia or another cellular source, these data provide
support for the hypothesis that delipidation of APOE occurs when APOE is sequestered into Aβ
plaques. One previous study postulated that endosomal/lysosomal compartments containing
concentrated Aβ and acidic pH creates an ideal setting for Aβ to self-assemble (181). Kinetic
studies demonstrate that the acidic pH environment mirroring lysosomal compartments also
facilitates the propensity of APOE to self-associate (182), perhaps pinpointing the late
endosome/lysosome as a contending site for poorly-lipidated APOE to seed and interact with Aβ
aggregates (53). Whether poorly-lipidated APOE produced by cells acts as a pathological seed to
promote Aβ accumulation or whether APOE dissociates from its lipid particles by another
mechanism after being incorporated into insoluble plaques remains unknown and will be an
important question to answer. Future immunoprecipitation studies are required to ascertain
whether poorly-lipidated APOE is present at the biochemical level.
In vivo studies have established that the lipidation state of APOE strongly influences
amyloid pathology in the brain (27, 44, 75). APP transgenic mice deficient in the transporter
ATP binding cassette transporter A1 (Abca1) gene have decreased lipid associated with APOE
along with increased plaque burden, greater percentage of insoluble APOE that is co-deposited
with insoluble Aβ (183), and reduced Aβ clearance in APOE4 mice (184). Meanwhile,
overexpression of Abca1 or treatment with drugs that increase APOE lipidation strongly reduces
Aβ plaque deposition in APP transgenic mice (77, 78). In humans, APOE4 carriers have more
lipid-depleted APOE in the CSF compared to non-APOE4 carriers (76). Therefore, in our study,
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degradation of poorly-lipidated APOE that may adopt a toxic gain of function by seeding Aβ
plaques and/or hindering Aβ efflux from the central nervous system (CNS) appears to neutralize
CAA-mediated toxic effects while improving vasomotor function. Recovery of endothelial and
smooth muscle cell function that is impaired in CAA may restore blood-brain barrier dysfunction
and improve cerebral blood perfusion to promote the transport of toxic waste products through
the glymphatic and/or periarterial drainage pathways. As recent studies have uncovered the vital,
multifaceted roles of pericytes on BBB maintenance and capillary blood circulation (185, 186),
accounting for over 90% of the vascular length (187), follow up experiments examining whether
HAE-4 restores BBB degeneration in the cerebrovasculature that is exacerbated in APOE4
carriers is critical (109).
Previous studies established that certain Aβ antibodies with Fcγ receptor effector function
that target the N-terminus or aggregated forms of Aβ increase the incidence of ARIA in clinical
trials (165); whereas, less ARIA was reported with Aβ antibodies without effector function (141)
or that prominently bind monomeric versus aggregated Aβ (188, 189). Treatment with HJ3.4,
which binds Aβ at the N-terminus, did not exacerbate microhemorrhages but also had no effect
on plaque deposition. The lack of effects on microhemorrhages was perhaps a result of limited
target engagement, poor BBB penetrance, or minimal recruitment of microglia to parenchymal
and vascular Aβ plaques by HJ3.4. Follow-up experiments are necessary to resolve these
questions. Although ARIA is represented by both edema and hemorrhagic events, we only
modeled microhemorrhages, as there is no readily available model to detect antibody-mediated
edema responses. In our studies, HAE-4 contained a functional Fcγ receptor, but repetitive
treatment did not increase microhemorrhages. This exciting finding suggests that the occurrence
of ARIA results from a fundamentally different mechanism of action between APOE and Aβ
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antibodies and that the effector function in an APOE antibody is not sufficient for eliciting
microhemorrhages. Interestingly, donezumab also did not show exacerbation of
microhemorrhages in mice until treatment in humans revealed the presence of ARIA-E in over a
quarter of participants. In clinical trials, participants tend to develop ARIA-E more readily than
ARIA-H, suggesting that perhaps ARIA-E is a more sensitive measure of BBB defects and/or
ARIA-E and ARIA-H have mechanisms that may be mutually exclusive. Whether ARIA-E
and/or ARIA-H is causative for the neurological symptoms is unknown. Nonetheless, an
approach for measuring antibody-mediated edema would be very useful for the preclinical
testing of antibodies. Although our current study demonstrates that chronic treatment with HAE4 reduces parenchymal and vascular Aβ deposits whereas chi-Adu does not while simultaneously
eliciting microhemorrahges, the underlying mechanism for this discrepancy is unknown. Is it
related to glial-induced neuroinflammation on Aβ removal and the severity of
microhemorrhages? These questions will be explored in Chapter 4.
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3.6 Figures and tables

Figure 3.1 | Chi-Adu treatment reduces amyloid burden in a mouse model of parenchymal
Aβ plaques
A, Schematic schedule of antibody treatment in 5XFAD (line 6799) mice expressing murine
Apoe (Control IgG, n = 10; chi-Adu, n = 9). B, 3.5-month-old 5XFAD mouse brain sections
stained with HJ3.4B for pan-Aβ and C, percent area quantification of parenchymal Aβ plaque
coverage in cortex. D, E, Assessment of X34 coverage in cortex for fibrillar parenchymal
plaques. Big panel: Scale bar = 500 µm. Small panel: Scale bar = 100 µm. Control = Control
IgG. Chi-Adu = Chimeric Aducanumab. Data expressed as mean ± SEM, student’s t-test (two58

sided). ***P < 0.001, ****P < 0.0001. No other statistical comparisons are significant unless
indicated.

Figure 3.2 | HAE-4 reduces parenchymal Aβ plaques and CAA in 5XE4 mice
A, Schematic timeline of antibody treatment in 5XFAD (line 7031) x APOE4+/+ (5XE4) mice
with CAA assessed at 10-months-old. B–E, Representative immunostainings of HJ3.4B for
mixed pan-Aβ pathology (B) and quantification of percent area in cortex of total Aβ (C),
parenchymal Aβ plaques (D), and CAA (E). Control IgG, n = 13; HAE-4, n = 14, chi-Adu, n =
12. Scale bar = 750 µm. F–I, Thioflavin S (ThioS) staining for insoluble, fibrillar plaques (F)
with quantification for area covered by total amyloid (G), parenchymal plaques (H), and CAA
(I) pathology in overlaying cortex (Control IgG, n = 12; HAE-4, n = 14, chi-Adu, n = 12). Scale
bar = 750 µm. J, K, Insoluble Aβ40 (J) or Aβ42 (K) protein concentrations from bulk cortical
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tissue lysate homogenized in guanidine measured by ELISA and normalized to total protein
concentration in cortex (Control IgG, n = 13; HAE-4, n = 14, chi-Adu, n = 12). L–O, Forebrain
vessel isolation paradigm using dextran gradient centrifugation of a separate 5XE4 cohort treated
with antibodies (L; Control IgG, n = 13; HAE-4, n = 12, chi-Adu, n = 13). Isolated brain
vasculature fluorescently stained for X34+ fibrillar CAA, endothelial marker CD31, and nuclei
marker TOPRO3. Scale bar = 150 µm. (M). Insoluble Aβ40 (N) and Aβ42 (O) protein
concentrations assessed by ELISA from forebrain-extracted vessels sonicated in guanidine-HCL
and normalized to total protein concentration. Control = Control IgG. Chi-Adu = Chimeric
Aducanumab. Data expressed as mean ± SEM, one-way ANOVA with Tukey’s post hoc test
(two-sided) performed for all statistical analyses except Kruskal-Wallis test with Dunn’s
multiple comparisons test (two-sided) for parenchymal Aβ/ThioS, and Aβ40 analysis (D, H, J).
*P < 0.05, **P < 0.01. No other statistical comparisons are significant unless indicated.

Figure 3.3 | HAE-4 strongly reduces Aβ parenchymal plaques of varying sizes in 5XE4 mice
A, Stratification of Aβ plaques by size for analysis of plaque distribution in cortex from 10month-old antibody-treated 5XE4 mice (50 mg/kg, weekly i.p. for 8 weeks; Control IgG, n = 13;
HAE-4, n = 14, chi-Adu, n = 12). Two-way ANOVA with Tukey’s post hoc test (two-sided). B,
Assessment of the number of large Aβ plaques (>1,715 µm2). Control = Control IgG. Chi-Adu =
Chimeric Aducanumab. Data expressed as mean ± SEM, one-way ANOVA with Tukey’s post
hoc test (two-sided). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. No other statistical
comparisons are significant unless indicated.
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Figure 3.4 | No sex-dependent effect of HAE-4 or chi-Adu on Aβ plaque pathology or
microhemorrhages
10-month-old 5XE4 mice treated for 8 weeks were evaluated for sex-dependent differences in
response to peripheral antibody administration (50 mg/kg, i.p., weekly; Control IgG, n = 11–12;
HAE-4, n = 13, Adu, n = 12). A–C, Analysis of HJ3.4B immunoreactivity to determine percent
coverage of total cortical Aβ (A: significant effect of treatment (F2,33 = 4.585, P = 0.018) but no
effect of sex (F1,33 = 0.328, P = 0.571) or interaction (F2,33 = 0.550, P = 0.582)), Aβ parenchymal
(B: significant effect of treatment (F2,33 = 4.242, P = 0.023) but no effect of sex (F1,33 = 0.578, P
= 0.453) or interaction (F2,33 = 0.475, P = 0.626)), or CAA (C: significant effect of treatment
(F2,33 = 3.332, P = 0.048) but no effect of sex (F1,33 = 0.009, P = 0.923) or interaction (F2,33 =
0.452, P = 0.640)) pathology in male and female 5XE4 mice. D–F, Quantification of area
covered by total ThioS (D: significant effect of treatment (F2,32 = 5.432, P = 0.009) but no effect
of sex (F1,32 = 0.553, P = 0.463) or interaction (F2,32 = 0.026, P = 0.976)), parenchymal (E:
significant effect of treatment (F2,32 = 4.568, P = 0.018) but no effect of sex (F1,32 = 0.524, P =
0.475) or interaction (F2,32 = 0.066, P = 0.937)), and CAA (F: trend towards significant effect of
treatment (F2,32 = 2.854, P = 0.072) but no effect of sex (F1,32 = 0.269, P = 0.608) or interaction
(F2,32 = 0.006, P = 0.995)) fibrillar plaques separated by sex. G, H, Prussian blue staining
analysis segregated by sex for microhemorrhage frequency (G: significant effect of treatment
(F2,30 = 7.900, P = 0.002) but no effect of sex (F1,30 = 0.095, P = 0.760) or interaction (F2,30 =
0.007, P = 0.993)) and size (H: significant effect of treatment (F2,30 = 10.27, P = 0.0004) but no
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effect of sex (F1,30 = 0.008, P = 0.931) or interaction (F2,30 = 1.005, P = 0.378)). Control =
Control IgG. Chi-Adu = Chimeric Aducanumab. Data expressed as mean ± SEM, two-way
ANOVA with Tukey’s post hoc test (two-sided). *P < 0.05, **P < 0.01.

62

63

Figure 3.5 | HAE-4 selectively binds dense core fibrillar plaques whereas chi-Adu
recognizes both dense core and diffuse Aβ plaques
A, B, Triple co-staining of X34, HAE-4 (A), and chi-Adu (B) in unfixed, cortical tissue of a 22month-old 5XE4 male mouse for plaque-binding profile of antibodies to either APOE (HAE-4)
or Aβ (chi-Adu). Left panel in A and B: parenchymal plaque. Right panel: CAA. Scale bar = 50
µm. C–H, Human autopsy brain tissue from patients (n = 1 per group) including CAA (C, D),
AD only (E, F), or no pathology (G, H) stained with X34, HJ3.4 (pan-Aβ), HAE-4, or chi-Adu.
Scale bar = 50 µm. Chi-Adu = Chimeric Aducanumab.
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Figure 3.6 | Chi-Adu exacerbates CAA-associated brain microhemorrhages whereas HAE4 does not
A, Dual labeling of ThioS+ fibrillar CAA and Prussian blue for hemosiderin deposits revealed
CAA-associated microhemorrhages (right panel: microhemorrhage digitally converted to yellow)
in 10-month-old 5XE4 mice. Scale bar = 100 µm. B, C, Prussian blue staining analysis for
microhemorrhage frequency (B) and size (C) in 5XE4 mice dosed weekly for 8 weeks with
antibody treatment (50 mg/kg, i.p.; Control IgG, n = 11; HAE-4, n = 13, chi-Adu, n = 12). Oneway ANOVA with Tukey’s post hoc test (two-sided). D, Number of microhemorrhages binned
in 100 µm2 increments for frequency/size distribution. Control = Control IgG. Chi-Adu =
Chimeric Aducanumab. Data expressed as mean ± SEM, two-way ANOVA with Tukey’s post
hoc test (two-sided). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. No other statistical
comparisons are significant unless indicated.
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Figure 3.7 | Anti-Aβ antibody HJ3.4 does not alter fibrillar plaques or microhemorrhage
severity
A, B, Dual labeling of ThioS+ fibrillar plaques (A) and Prussian blue for hemosiderin deposits
(B) in 10-month-old 5XE4 mice. Control = Control IgG. Chi-Adu = Chimeric Aducanumab. 8month = 8-month-old untreated 5XE4 mice. Data expressed as mean ± SEM, one-way ANOVA
with Tukey’s post hoc test (two-sided) (A) and Kruskal-Wallis test with Dunn’s multiple
comparisons test (two-sided) for data not normally distributed (B). *P < 0.05, **P < 0.01. No
other statistical comparisons are significant unless indicated.
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Figure 3.8 | HAE-4 restores vascular function to CAA-laden leptomeningeal arteries in
vivo
A, Schematic of antibody treatment and experimental design in 12-month-old 5XE4 mice for
assessment of pial vascular function using endothelial-dependent ACH, vascular smooth muscle
cell-dependent SNAP, and CO2-induced hypercapnia. B, Representative images of X34+ CAA on
vessel segment at baseline or after ACH exposure. C–E, Percent vasodilatory change calculated
at baseline and after ACH (C, Control IgG, n = 7; HAE-4, n = 8, chi-Adu, n = 7, Non Tg, n = 4),
SNAP (D, P = 0.047 treatment interaction with two-way ANOVA between Control IgG, HAE-4,
and Adu denoted with “*”; Control IgG, n = 7; HAE-4, n = 8, chi-Adu, n = 6, Non Tg, n = 4), or
hypercapnia (E, Control IgG, n = 6; HAE-4, n = 8, chi-Adu, n = 6, Non Tg, n = 4). Scale bar =
25 µm. ACH = Acetylcholine. SNAP = S-Nitroso-N-acetyl-DL-penicillamine. Control = Control
IgG. Chi-Adu = Chimeric Aducanumab. Non Tg = Non-transgenic. Green arrowheads indicate
changes in percent dilation from baseline. Data expressed as mean ± SEM, one-way ANOVA
comparison with Tukey’s post hoc test (two-sided) between treatment groups in vessels with less
or more than 50% CAA coverage unless otherwise stated. *P < 0.05, **P < 0.01. Non-transgenic
(n = 4) versus control IgG comparisons: ACH, P < 0.001; SNAP, P < 0.05; Hypercapnia, P <
0.05. Non-transgenic (n = 4) versus chi-Adu comparisons: ACH, P < 0.001; SNAP, P = 0.097.
No other statistical comparisons are significant unless indicated or stated.
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Figure 3.9 | Mean baseline vessel diameter and CAA coverage are consistent between
treatment groups
12-month-old 5XE4 mice were peripherally administered weekly antibody treatments prior to in
vivo vascular imaging (50 mg/kg, i.p., 8 weeks, Control IgG, n = 7; HAE-4, n = 8, chi-Adu, n =
7, Non Tg, n = 4). A, B, Baseline leptomeningeal vessel diameter measurements (A; one-way
ANOVA with Tukey’s post hoc test, two-sided) and percent CAA on quantified vessel segments
(B). Control = Control IgG. Chi-Adu = Chimeric Aducanumab. Data expressed as mean ± SEM,
two-way ANOVA with Tukey’s post hoc test (two-sided). No other statistical comparisons are
significant unless indicated.
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Figure 3.10 | No binding of HAE-4 to APOE from immortalized astrocytes in vitro
Recombinant APOE or astrocyte-secreted APOE in media coated at 0.5 or 2 µg/mL on 96-well
plates and captured with increasing concentrations of HAE-4. rE2/4 = recombinant APOE2 or
APOE4. Astro-E2/3/4 = astrocyte-secreted APOE2/3/4. Purified APOE particles from Michael
Strickland.
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Figure 3.11 | HAE-4 binding of APOE in Aβ plaques but not in a tau mouse model
A–E, Immunostainings of unfixed brain section from APOE4+/+ mouse with HAE-4 (A), APP/E4
mouse with HAE-4 (B), and a 10-month-old P301S/APOE4+/+ mouse with HAE-4 (C), a control
IgG (D), or AT8 (E). Scale bar = 250 µm. P301S/E4 = P301S/APOE4+/+.

Table 3.1 | Demographics of human brain tissue
Relevant variables of patient brain tissue with CAA, AD, or no pathology stained with X34,
HJ3.4, HAE-4 or chimeric Aducanumab (refers to Figure 3.5).

Table 3.2 | No difference in blood gas measurements at baseline and hypercapnia
12-month-old 5XE4 mice treated weekly with antibodies for live imaging (50 mg/kg, i.p., 8
weeks, Control IgG, n = 7; HAE-4, n = 8, chi-Adu, n = 7, Non Tg, n = 4). Blood gases were
regulated and samples with measurements for pH, pCO2, and SO2 were collected before baseline
imaging and during hypercapnia. Control = Control IgG. Chi-Adu = Chimeric Aducanumab.
Data expressed as mean ± SEM, one-way ANOVA with Tukey’s post hoc test (two-sided). No
statistical comparisons are significant.
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Chapter 4:
Neuroinflammatory response and
mechanisms of APOE and Aβ targeting
antibodies in a mouse model with Aβ deposits
in the brain parenchyma and vasculature
This chapter is partially adapted from the following manuscript
M. Xiong, H. Jiang, J. R. Serrano, E. R. Gonzales, C. Wang, M. Gratuze, R. Hoyle, N. Bien-Ly,
A. P. Silverman, P. M. Sullivan, R.J. Watts, J.D. Ulrich, G.J. Zipfel, D. M. Holtzman, APOE
immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving
cerebrovascular function. Sci. Transl. Med. 13, eabd7522 (2021).
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4.1 Summary
In Chapter 3, we described that the anti-human APOE antibody HAE-4 reduced
parenchymal and vascular Aβ and rescued cerebrovascular dysfunction, whereas chimeric
aducanumab (chi-Adu) did not (190). However, the mechanisms underlying these two antibodies
and their discrepancies are unclear. Antibodies on an IgG2a backbone like HAE-4 and chimeric
aducanumab (chi-Adu) are expected to exert their effects by engaging microglia through
interactions with Fcγ receptors. In this current study, we explored the effects of HAE-4 and chiAdu on neuroinflammation in both subacute and chronic treatment paradigms. Although HAE-4
acutely stimulated reactive and homeostatic microglial and certain reactive astrocytic genes that
were ameliorated chronically, chi-Adu upregulated homeostatic microglial genes as well as
genes that resembled disease-associated astrocytes. Furthermore, the anti–Aβ antibody
exacerbated microhemorrhage severity, which highly correlated with reactive astrocytes
surrounding CAA. HAE-4 not only reduced amyloid but also dampened reactive microglial,
astrocytic, and proinflammatory-associated genes in the cortex. These results suggest that by
working in concert with activated microglia, targeting APOE in the core of both CAA and
plaques could ameliorate amyloid pathology while protecting cerebrovascular integrity and
function.
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4.2 Introduction
Amyloid-related imaging abnormalities (ARIA) is a significant adverse effect from
treatment with Aβ antibodies and yet little is known about the mechanism. ARIA is subdivided
into ARIA-E (edema) visualized on fluid-attenuated inversion recovery (FLAIR) sequences and
ARIA-H (microhemorrhages and superficial siderosis) on gradient echo (T2*-GRE) sequences.
Certain Aβ antibodies with Fcγ receptor function that target the N-terminus or aggregated forms
of Aβ increase the incidence of ARIA in clinical trials (168). In contrast, less ARIA was reported
with Aβ antibodies without effector function (141) or that prominently bind monomeric versus
aggregated Aβ (188, 189). Findings from clinical trials revealed that a major risk factor for
ARIA is administration of high antibody dose and increasing numbers of the APOE4 gene (162).
Although the pathogenic mechanism for ARIA is unknown, ARIA is proposed to reflect
antibody-mediated clearance of substantial Aβ exiting the perivascular spaces. Indeed,
“hotspots” of rapid amyloid clearance by anti-Aβ antibody gantenerumab was associated with
ARIA-E (www.alzforum.org). From a clinical and neuroimaging perspective, ARIA shares
similar features to patients diagnosed with spontaneous CAA-related inflammation (CAA-ri)
(105). CAA-ri is marked by inflammatory perivascular immune infiltrate and major
histocompatibility complex (MHC) class II-expressing microglia (191, 192) surrounding blood
vessels with enhanced Aβ clearance, suggesting that perhaps an immune response as a
consequence to vascular amyloid in combination with rapid amyloid shift to perivascular spaces
may underlie ARIA.
In our current study, HAE-4-mediated reduction of CAA and plaques is highly effective
and also well-tolerated in mice with pre-existing CAA and Aβ plaques (Chapter 3). HAE-4
specifically binds to poorly-lipidated APOE in the core of plaques and recruits phagocytic
73

microglia (Chapter 2). Moreover, we discover that this form of APOE is also found in CAA.
HAE-4 reduces CAA, likely by direct cellular uptake and elimination of Aβ by microglia.
Reactive microglia and astrocytes surrounding parenchymal Aβ plaques is a common
neuropathological feature in humans and APP transgenic mice (193). In the hereditary
amyloidosis-Dutch type (HCHWA-D) mouse model where CAA is extensive, there is
widespread astrocytosis and microgliosis in close vicinity to CAA-laden vessels, but this glial
response was absent in cortical areas devoid of CAA in the same mice (20). In humans,
astrocytes and microglia are also detected around CAA, particularly surrounding capillary-CAA
(194). Furthermore, microglia engulf hemosiderin from lysed red blood cells and is visible with
Perl’s Prussian blue staining as microhemorrhages. Whether microglia and astrocytes are
responding to amyloid accumulation along blood vessels or potential leakage of blood proteins is
unknown.
To investigate the role of antibody-mediated neuroinflammation on removal of Aβ, we
assess gene transcripts and protein changes in microglia and astrocytes after HAE-4 or chi-Adu
treatments. We hypothesized that whereas HAE-4 is selective for poorly-lipidated APOE within
the core of fibrillar plaques, chi-Adu is indiscriminately binds both fibrillar and diffuse-like Aβ
deposits, which may overstimulate a vascular immune response to disrupt the integrity and
function of the cerebrovasculature.

4.3 Experimental methods
For methods on animal generation, tissue harvesting/preparation, antibody production,
and histology, see Chapter 3.
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Confocal imaging and colocalization analyses. See Chapter 3 for details. For colocalization
analysis, automatic thresholding method “Otsu” was set for plaques, microglia, and astrocytes,
followed by colocalization between plaques and microglia or astrocytes using built-in image
calculator AND operator. The percent of colocalization between the two channels was
normalized to respective plaque load (total, parenchyma, or CAA). Images were processed and
analyzed after blinding to treatment.
Gene expression assays. Total RNA was extracted from anterior mouse cortex using RNeasy
Mini kit (Qiagen, 74106). Following the manufacturer’s protocols, cDNA was prepared with the
High-Capacity RNA-to-cDNA kit (Applied Biosystems, 4387406). Automated qPCR reactions
using Taqman probes to determine relative gene expression were performed using Fluidigm
Biomark HD by the Genome Technology Access Core at Washington University. Initial analyses
were normalized to housekeeping gene Gapdh (chronic study) and subsequent analyses included
the usage of more housekeeping genes (Gapdh, Actin, Ywhaz) to be normalized against using
their geometric mean (acute study). Expression fold changes were normalized to control IgG and
heatmaps were generated using Phantasus v1.5.1.
Dissociation and sorting of astrocytes and microglia. Mice were transcardially perfused with
chilled PBS with 1% Glutamax for 3 minutes. The hippocampus, thalamus, cerebellum, and right
hemisphere were flash-frozen and stored at -80 °C for future analysis. The cortex from the left
hemisphere was dissected and immersed in PBS with 1% Glutamax and immediately dissociated
using the Adult Brain Dissociation Kit (Miltenyi Biotec 130-107-677) following the
manufacturer’s instructions. All cells were stained on ice for 20 minutes with fixable violet
live/dead cell staining dye (L34955, Thermo Fisher Scientific), followed by incubation in mouse
Fcγ receptor blocker (553141, BD Biosciences) for 5 minutes. Dissociated cells were then
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stained with CD11b-APC-Cy7 (557657, BD Biosciences) and ACSA-2-PE (130-123-284,
Miltenyi Biotec) supplemented with brilliant stain buffer (563794, BD Biosciences) for 20
minutes on ice. Washes were implemented between each stain with Wash Buffer (PBS + 0.5%
BSA + 1X EDTA) and cells were centrifuged down at 1000 xg for 5 min at 4 °C. Cells were
resuspended in Wash Buffer and sorted with BD FACSAria II flow cytometer. Compensation
was performed using AbC Anti-Rat/Hamster Bead Kit (A10389, Thermo Fisher Scientific), AbC
Anti-Mouse Bead Kit (A10344, Thermo Fisher Scientific), and ArC Amine Reactive
Compensation Bead Kit (A10346, Thermo Fisher Scientific).

4.4 Results
4.3.1 HAE-4 acutely upregulates proinflammatory genes that are mitigated chronically
Amyloid removal by HAE-4 and chi-Adu has been reported to be facilitated by enhanced
microglial recruitment to parenchymal plaques (143, 154). In a model with CAA, we
hypothesized that chi-Adu engagement with amyloid in vessels without effective clearance may
stimulate increased glial-associated inflammation surrounding vessels resulting in increased
hemorrhaging events. To capture acute gene expression changes over a shorter timeframe
without bias from substantial plaque removal, we injected 11-month 5XE4 mice with abundant
existing CAA/plaques 4 times across 10 days with HAE-4, chi-Adu, or control IgG (50 mg/kg,
i.p.; Figure 4.1). Although 12–14 mice were treated per group, only mice derived from male
5XFAD transgene carriers were used, because female 5XE4 mothers produced 5XE4 pups that
had minimal or no amyloid pathology and plaque-associated gliosis (Figure 4.2). In this
subacute treatment paradigm, there was not a significant reduction of X34+ fibrillar plaques
although there was a trend with HAE-4 (Figure 4.1B–D, Figure 4.1B: P = 0.10; Figure 4.1D: P
= 0.12). Next, we evaluated the amount of reactive microglia using CD45. HAE-4 treatment
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elicited a large increase in CD45+ microglial staining that was stronger than the effect by chiAdu (Figure 4.1E, F). Furthermore, HAE-4 upregulated both homeostatic (Cx3cr1, Tmem119,
P2ry12) and reactive or disease-associated (Trem2) (195, 196) microglial genes in the cortex,
whereas chi-Adu significantly increased homeostatic (P2ry12) microglial gene expression
(Figure 4.1G). Both treatments stimulated reactive astrocytes, with chi-Adu upregulating more
astrocytic genes (Figure 4.1G). Furthermore, acute HAE-4 and chi-Adu treatments also
increased certain proinflammatory cytokine genes likely released by reactive microglia,
astrocytes, or vascular cells (Figure 4.1G). The striking upregulation of gliosis after acute
treatment prompted us to also assess the effects in chronically-treated mice. In 10-month-old
5XE4 mice treated with HAE-4, chi-Adu, and control IgG for 2 months, we observed that HAE4 downregulated certain genes expressed in microglia, astrocytes, and proinflammatory
cytokines, likely from the reduction of plaque-associated gliosis (Figure 4.3A). Moreover, after
acute HAE-4 treatment, there was also an initial upregulation of certain genes related to the
vasculature and reactive oxygen species that were ameliorated after chronic treatment (Figure
4.4). Aquaporin-4 (AQP4), a water channel localized predominantly in the astrocytic endfeet that
mediates fluid efflux and is essential for the postulated glymphatic pathway (197, 198), was
decreased acutely and increased after chronic HAE-4 treatment (Figure 4.5), suggesting restored
function to GFAP+ astrocytes and potentially enhancement of Aβ clearance. Overall, these
results suggest that in HAE-4-treated mice, there was an initial upregulation of inflammatory
genes associated with microglia, astrocytes, and vascular cells that was mitigated after chronic
treatment and plaque removal, whereas chi-Adu provoked an initial inflammatory response that
was sustained chronically.
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4.3.2 Antibody treatments stimulate differential glial responses to CAA and plaques
Our gene expression study investigated global mRNA changes in 5XE4 cortex, but any
specific changes on a per plaque basis may be masked by bulk qPCR. When we assessed glia at
the protein/plaque level using immunofluorescent staining, there was robust Iba1+ microglia
colocalization with both CAA and parenchymal plaques in mice treated acutely or chronically
with HAE-4 (Figure 4.3B, D–F; Fig. Figure 4.6A–C). In contrast, there was a significant
increase in GFAP+ astrocytes colocalized with CAA only in chi-Adu-treated mice in the chronic
treatment paradigms (Figure 4.3C, H–J) but with only a trend after subacute treatment (Figure
4.6D–F, Fig. S6F: P = 0.07). We then assessed whether glial clustering around CAA was linked
to microhemorrhages. Whereas the amount of Iba1+ microglia surrounding CAA did not
correlate with microhemorrhage number (Figure 4.3G), the amount of GFAP+ astrocytes in the
immediate vicinity of CAA strongly correlated with microhemorrhage incidence but only in the
chi-Adu group (Figure 4.3K, P < 0.05). Furthermore, the subacute treatment led to no changes
in microhemorrhage events, suggesting that microhemorrhages develop after chronic dosing and
glial alterations precede microhemorrhage events (Figure 4.7). Moreover, Igtp, a gene associated
with LPS-induced vascular inflammation in astrocytes (Hasel et al., unpublished) was detected
only after acute chi-Adu treatment in a preliminary cohort (Figure 4.8). Combined, these results
suggest that somehow an anti-Aβ but not an anti-APOE antibody differentially stimulates a
chronic astrocyte reactivity around CAA that contributes to CAA-associated microhemorrhages.
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4.5 Discussion
The efficacy of amyloid-targeting immunotherapy harnesses the interactions between two
complex systems: the immune and central nervous systems. In this study, we explore the
differential effects of an APOE versus an Aβ antibody on neuroinflammation in the CNS. We
pose the following questions: [1] Does HAE-4 treatment have downstream benefits on
inflammatory gene expression or vascular function in CAA-laden vessels? [2] Are there
fundamental mechanistic differences between the effects of an APOE antibody versus an Aβ
antibody and how do they relate to vascular dysfunction?
We report that HAE-4 has a synergistic effect in reducing CAA and Aβ parenchymal
plaques while neutralizing Aβ-mediated vascular toxicity even after plaque onset (Figure 4.9).
Our previous results show that parenchymal plaque removal is dependent on Fcγ receptormediated phagocytosis and clearance of Aβ (154) (Chapter 2). Here, we showed a baseline
expression of activated perivascular microglia surrounding plaques and CAA (20) that increased
after HAE-4 treatment. Specifically, HAE-4 enhanced both activated and homeostatic
microgliosis. Microgliosis was more pronounced around parenchymal plaques and to a lesser
extent around CAA, perhaps because APOE is only a small fraction of the protein that is codeposited along with Aβ in CAA, which accumulates in the smooth muscle basement membrane
and then later intercalates between smooth muscle cells. Despite differences in microglial
clustering, HAE-4 decreased Aβ deposition in both brain parenchyma and vessels. Gene
expression analysis revealed that in a subacute paradigm, HAE-4 upregulated certain diseaseassociated microglial genes, as expected, but also homeostatic microglial genes including
P2ry12, Tmem119, and cx3cr1. Microglia have been shown to rapidly migrate to locations of
focal, laser-induced microvascular injuries that mimic spontaneous microhemorrhages (199,
79

200). Interestingly, the purinergic receptor P2ry12 expressed exclusively on microglia was
necessary for microglial-mediated closure of the BBB after injury (201) and modulation of
cerebral blood flow (202) . Therefore, it may be possible that while reactive microglia worked to
remove plaques/CAA that may induce microhemorrhages, the simultaneous activation of
P2ry12+ microglia assisted in sealing potential cerebral bleeds from CAA removal while
promoting blood flow. Although chi-Adu also upregulated P2ry12, binding of chi-Adu to
widespread Aβ without effective clearance may lock the brain in a sustained state of chronic
inflammation that may give rise to ARIA. Recently, imaging from the anti-Aβ antibody
gantenerumb trials revealed “hotspots” of rapid antibody-mediated amyloid clearance that was
associated with ARIA-E (www.alzforum.org). The association with ARIA-H was not shown. In
our study, we did not detect substantial parenchymal Aβ clearance after chi-Adu, however
ARIA-H was exacerbated. These results suggest that ARIA-E and ARIA-H are evoked by
different mechanisms or that rapid amyloid clearance, although associated with ARIA-E, is not
necessary to elicit ARIA-H.
HAE-4 may also exert its therapeutic effects by trafficking less Aβ through the
perivascular drainage pathway following parenchymal Aβ removal. In AD and CAA, impaired
perivascular clearance potentiates CAA buildup (41). HAE-4-mediated removal of vascular Aβ
plaques may reverse CAA-induced perivascular drainage complications. Although certain Aβ
antibodies that cause CAA-related hemorrhages or transiently leaky vessels may resolve over
time with repeated immunization (167), we show that targeting APOE with HAE-4 did not
stimulate adverse vascular effects. In our study, we found that ARIA (measured by
microhemorrhages) did not arise from initial upregulated focal inflammation related to antibody
target engagement on CAA. Whether HAE-4 removal of CAA led to extravasation of blood-
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derived proteins (i.e. immunoglobulin, fibrinogen) is unknown and remains open questions to
answer in the future.
Here, we discover a potential mechanism for ARIA that is astrocyte-mediated. Chi-Adu
administration stimulated reactive astrocyte around CAA that resembled disease-associated
astrocytes (203) and correlated with microhemorrhage severity. The chronic reactivity of these
GFAP+ astrocytes may lose their normal functions, such as maintenance of the blood-brain
barrier, and adopt a disease-associated function that leads to leaky vessels and brain
hemorrhages. Although we did not directly colocalize GFAP+ astrocytes with hemorrhagic
events, a previous study revealed that GFAP+ astrocytes surrounded laser-induced
microhemorrhages (199). Longitudinal in vivo imaging of GFAP-expressing astrocytes could
assist in capturing both spatial and temporal changes of astrocytes to hemorrhagic events and
infiltration of blood-derived products and/or cells. A major challenge for deciphering the
significance of these astrocytes to Aβ antibody treatment-induced ARIA is to determine if
similar astrocyte activation around CAA occurs in humans following treatment with antibodies
to aggregated forms of Aβ. Also, since ARIA generally resolves over time, it may be difficult to
capture and understand in human studies. Further studies in mice could be performed by
isolating and characterizing vessel-associated astrocytes. In our gene expression data, we
measured an increase in Il1α, Tnfα, and C1q cytokines that were described to be released by
microglia to induce A1 astrocytes (204) but, in contradiction, we detected little evidence that chiAdu morphologically stimulated reactive microglia, suggesting these proinflammatory cytokines
may originate from another cellular source. This question can be resolved by performing singlecell RNA sequencing to examine cell-specific effects after antibody treatment. The function of
these astrocytes and whether they directly cause microhemorrhages or are a result of infiltrating
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peripheral proteins is currently under investigation. Interestingly, subacute treatment after 10
days did not elicit ARIA. There are numerous studies that detect microhemorrhages after chronic
treatment with Aβ vaccines or immunotherapies (164–166, 205, 206). One study tracked
microhemorrhage events monthly and reported an increase after two months of weekly
peripheral Aβ antibody injections (164). In the bapineuzumab trials, the average number of
infusions was 2.4 (13 weeks between infusions) before detection of ARIA-E (207). Although
there are variations in CAA/plaque severity and onset between mouse models and antibodies
administered, these data suggest that a certain period of incubation is necessary before
microhemorrhages are elicited. It is possible that vessels are transiently leaky at this point and
blood-derived proteins such as fibrinogen or albumin would capture these earlier changes (208).
Interestingly, although subacute treatment with chi-Adu did not elicit microhemorrhages, there
was vascular inflammation marked by a novel interferon-γ-dependent gene Igtp that is only
present in astrocytes surrounding the BBB after inducing neuroinflammation with
lipopolysaccharide (LPS) (Hasel et al., unpublished). These data implicate a potential role in
astrocytes that precedes the occurrence of antibody-induced microhemorrhages.
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4.6 Figures and tables

Figure 4.1 | Strong glial response after acute HAE-4 and chi-Adu peripheral administration
A, Schematic design of 10.5-month-old 5XE4 mice injected once every 3 days for 4 times and
assessed at 11 months-of-age. B–D, Quantification of total X34+ (B), parenchymal (C), and
CAA (D) fibrillar plaques (Control IgG, n = 7; HAE-4, n = 7, chi-Adu, n = 5). E, F, CD45
(activated microglia) staining and quantification in cortex (Control IgG, n = 7 mice; HAE-4, n =
7 mice, chi-Adu, n = 5 mice). G, Heatmap analysis of bulk cortical microglial, astrocytic, and
pro-inflammatory cytokine gene expression pattern by qPCR (Control IgG, n = 6; HAE-4, n = 7,
chi-Adu, n = 5). “*” denotes statistical significance for HAE-4 versus control (*P < 0.05,
**P < 0.01, ***P < 0.001); “+” for chi-Adu versus control (+P < 0.05, +++P < 0.001).; “#” for
HAE-4 versus chi-Adu (#P < 0.05). Parench = Parenchymal. Control = Control IgG. Chi-Adu =
Chimeric Aducanumab. Data expressed as mean ± SEM, one-way ANOVA with Tukey’s post
hoc test (two-sided). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. No other statistical
comparisons are significant unless indicated.
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Figure 4.2 | Parental heritage of 5XFAD transgene determines the severity of amyloid
pathology and plaque-associated gliosis
A, 5XE4 pups derived from female (top) or male (bottom) transgenic 5XFAD carriers stained for
X34+ fibrillar plaques. B, Brain sections from female (top) or male (bottom) transgenic 5XFAD
carriers co-stained for X34+ fibrillar plaques, HJ15.7+ APOE, Iba1+ microglia, and GFAP+
astrocytes and imaged on the Nikon A1R+ confocal microscope.
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Figure 4.3 | HAE-4 and chi-Adu treatments stimulate differential glial responses to Aβ
plaques and CAA
A, Relative expression of microglial, astrocytic, and pro-inflammatory transcripts from bulk
cortex of antibody-treated 10-month-old 5XE4 mice (50 mg/kg, weekly i.p. for 8 weeks; Control
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IgG, n = 13; HAE-4, n = 13, chi-Adu, n = 12) measured via qPCR, clustered by antibody
treatment, and normalized to control IgG gene expression. “*” denotes statistical significance for
HAE-4 versus control (*P < 0.05, **P < 0.01); “#” for HAE-4 versus chi-Adu (#P < 0.05). Genes
analyzed using one-way ANOVA with Dunnett’s multiple comparisons test: S100β, GFAP, Vim,
IL1α. One-way ANOVA with Tukey’s post hoc test (two-sided) unless otherwise noted. B–C,
Representative images of co-staining using X34 for fibrillar plaques and Iba1 for microglia (B)
or GFAP for astrocytes (C) in cortex. D–G, Percent area of Iba1+ microglia colocalized with
total X34 (D), parenchymal (E), or CAA plaques (F), normalized to respective percent area of
plaque load (Iba1+X34+/X34+). Microglial colocalization with CAA correlated to
microhemorrhage number per section (G; Pearson correlation: r = 0.279, R2 = 0.078, P = 0.405,
control IgG (n = 11); r = 0.329, R2 = 0.108, P = 0.297, HAE-4 (n = 12); r = 0.232, R2 = 0.054, P
= 0.468, chi-Adu (n = 12)). H–K, Percent colocalization of GFAP+ astrocytes and total X34 (H),
parenchymal (I), or CAA plaques (J), normalized to respective percent area of amyloid load
(GFAP+X34+/X34+). Correlation between colocalized astrocyte/CAA and microhemorrhage
number per section (K; Pearson correlation: r = 0.105, R2 = 0.011, P = 0.759, control IgG (n =
11); r = 0.561, R2 = 0.315, P = 0.058, HAE-4 (n = 12); r = 0.748, R2 = 0.560, P = 0.005, chi-Adu
(n = 12)). Large panel: Scale bar = 50 µm. Small panel: Scale bar = 50 µm. Parench =
Parenchyma. Control = Control IgG. Chi-Adu = Chimeric Aducanumab. Data expressed as
mean ± SEM, one-way ANOVA with Tukey’s post hoc test (two-sided) for all group
comparisons except Kruskal-Wallis test with Dunn’s multiple comparisons test (two-sided) for
data not normally distributed (F, H, and I). *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001. No other statistical comparisons are significant unless indicated.
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Figure 4.4 | Endothelial markers are initially upregulated but become quiescent with
plaque removal after HAE-4 treatment
A, B, Vascular transcripts of 11-month-old 5XE4 mice dosed acutely (A; 1X every 3 days for 4
total injections, 50 mg/kg, i.p.; Control IgG, n = 6; HAE-4, n = 7, chi-Adu, n = 5), or 10-monthold 5XE4 mice chronically receiving weekly systemic administrations (B; 8 weeks, 50 mg/kg,
i.p.; Control IgG, n = 13; HAE-4, n = 13, chi-Adu, n = 12). C, D, Reactive oxygen species
(ROS)-related gene expression changes in acute (C) or chronic (D) antibody treatments. “*”
denotes statistical significance for HAE-4 versus control (*P < 0.05); “#” for HAE-4 versus chiAdu (#P < 0.05); “+” for chi-Adu versus control (+P < 0.05). Control = Control IgG. Chi-Adu =
Chimeric Aducanumab. Data expressed as mean ± SEM, one-way ANOVA with Tukey’s post
hoc test (two-sided). No other statistical comparisons are significant unless indicated.

Figure 4.5 | Aquaporin-4 expression decreases after acute treatment and then increases
after chronic treatment
A, B, Relative expression of AQP4 expression normalized to GFAP expression after acute (A) or
chronic (B) antibody treatments.
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Figure 4.6 | Acute HAE-4 and chi-Adu treatments promote bidirectional glial clustering
around Aβ plaques
5XE4 at 11-month-of-age following acute antibody dosing study (1X every 3 days for 4 total
injections, 50 mg/kg, i.p.) assessed for percent glial colocalization with fibrillar Aβ plaques
(Control IgG, n = 7; HAE-4, n = 7, chi-Adu, n = 5). A–F, Percent colocalization of Iba1+
microglia (A–C) or GFAP+ astrocytes (D–F) with total X34+ fibrillar plaques (A, D), in
parenchyma (B, E) or CAA (C, F), normalized by plaque load. Parench = Parenchyma. Control
= Control IgG. Chi-Adu = Chimeric Aducanumab. Data expressed as mean ± SEM, one-way
ANOVA with Tukey’s post hoc test (two-sided) and Dunnett’s post hoc test for (F). *P < 0.05,
**P < 0.01, ***P < 0.001. No other statistical comparisons are significant unless indicated.
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Figure 4.7 | No changes in microhemorrhage after acute antibody treatment
Prussian blue staining analysis for microhemorrhage frequency in 11-month-of-age 5XE4
following acute antibody dosing study (1X every 3 days for 4 total injections, 50 mg/kg, i.p.).
Pink = female. Blue = male. Data expressed as mean ± SEM, one-way ANOVA with Tukey’s
post hoc test (two-sided). No statistical comparisons are significant unless indicated.

Figure 4.8 | Igtp hotspots after acute chi-Adu treatment
RNAscope for Slc1a3 and Igtp was performed in 11-month-of-age 5XE4 following acute
antibody dosing study (1X every 3 days for 4 total injections, 50 mg/kg, i.p.). Colocalization of
Igtp/Slc1a3 (Merge) only in chimeric aducanumab group. Collaboration with Philip Hasel from
Liddelow Lab.
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Figure 4.9 | Schematic summary of differential HAE-4 and chi-Adu antibody effects in a
mouse model with robust CAA
HAE-4 preferentially binds to APOE within dense core plaques/CAA. Initially, HAE-4
stimulates mostly microglia and, to a lesser extent, astrocytes to cluster around plaques/CAA.
This leads to reduced amyloid burden and ameliorates downstream plaque-induced
gliosis/inflammation, providing a favorable microenvironment for restoring cerebrovascular
function. In a context with prominent CAA, chimeric Aducanumab (chi-Adu), which binds to
both diffuse and dense core plaques/CAA, initially elicits some microgliosis and more
astrocytosis. Reactive astrocytes particularly around blood vessels with CAA may lose their
function in maintaining the blood-brain barrier, leading to increased hemorrhages. Alternatively,
chi-Adu directly promotes microhemorrhages by an unknown mechanism to allow for the influx
of toxic blood proteins or infiltrating immune cells that may promote severe astrogliosis around
CAA. The recruitment of less microglia by chi-Adu may also hinder plaque clearance, leading to
limited reduction in gliosis and inflammation and consequently minimal improvements in
vascular function.
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Chapter 5:
Conclusions and future direction
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5.1 Limitations and advantages of APOE immunotherapy
Over the past two decades, enormous research efforts have targeted the development of
disease-modifying therapies to treat Alzheimer disease (AD). Candidate Aβ-targeting drugs have
several mechanisms of action aimed to reduce Aβ production via secretase inhibitors, inhibit
aggregation with small molecules, and facilitate Aβ clearance with immunotherapy. Passive
immunotherapy offers many advantages compared to other methods, namely: [1]
immunogenicity is not required, minimizing variability in antibody response and providing an
ideal approach to treat the elderly with compromised immune systems; [2] adverse effects are
easier to halt; [3] specific epitopes are targeted; [4] antibody administration is relatively painless.
However, there are also certain disadvantages, including: [a] minimal brain penetration, as only
0.1% of peripherally administered antibodies enter the brain (209); [b] reduced feasibility with
patients required to go in for monthly office infusions; [c] expensive due to high production of
antibody; [d] potential generation of antibodies targeting the antibody being administered that
may lead to adverse effects; [e] adverse effects from off-target binding. From an efficacy and
safety standpoint, we have discovered an antibody targeting poorly-lipidated APOE only found
in the core of plaques and CAA that has high efficiency with seemingly little adverse effects.
Therapeutic strategies that enhance the clearance of Aβ may be utilized in the treatment
of both AD and CAA, owing to the shared pathogenic mechanism of Aβ. In Chapters 2–4, we
demonstrate with different amyloid-depositing mouse models that an APOE-targeting antibody
HAE-4 can both prevent and treat amyloid pathology. Perhaps more importantly, HAE-4 also
reduces CAA without compromising vascular integrity, despite stimulating an initially strong
immune response essential for Aβ clearance. We have discussed several ongoing questions of
our studies in previous chapters, for example the cellular source and role of poorly-lipidated
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APOE as well as the implications of reactive astrocytes associated with CAA-induced
microhemorrhage. Here, we address other limitations to our study.
Although the APPPS1-21/APOE4+/+ (APP/E4) mice and 5XFAD/APOE4+/+ (5XE4)
mouse model that we used recapitulate parenchymal and CAA pathology in humans, these
models do not capture the full spectrum of AD. Both APP/E4 and 5XE4 mice do not develop
intracellular tau accumulation and tau-mediated cognitive deficits. Therefore, our findings
suggest that HAE-4 is highly effective in the early, preclinical phase of AD when there is
prominent neocortical Aβ but limited tau pathology. However, the effects of HAE-4 on the
clinical phase of AD that is also modulated by tau pathology are unknown. This question is
important to answer because microglial activation in the presence of mutated human tau has
recently been shown to exacerbate tauopathy (62, 210). Although HAE-4 does not promote
vascular complications, it will be important to understand the effect of HAE-4-induced
microgliosis on tauopathy, tau spreading, and tau-mediated neurodegeneration. We have
preliminary evidence that in the context of tau seeding in a model with mostly CAA (5XFAD
with floxed APOE4+/+), that HAE-4 ameliorates neuritic plaque (NP) tau, a type of tau pathology
containing AT8+ tau aggregates that localizes to dystrophic neurites and clusters around amyloid
cores (211). The reduction of NP tau was presumably from HAE-4 removal of amyloid, resulting
in an environment with less amyloid to seed (Figure 5.1). This suggests that in a model with Aβ
and early tau pathology, HAE-4 treatment is beneficial. Moreover, although microglial activation
is detrimental in a model of pure tauopathy, in the context of tau seeding, intact microglia
function reduces NP tau and dystrophic neurites (212). As CAA is associated with greater
neurofibrillary tangles and NP tau severity with APOE4 (32), it will also be interesting to
determine whether CAA enhances seeding of NP tau.
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Next, our studies would benefit from testing the therapeutic effects of HAE-4 in
APPPS1-21 or 5XFAD transgenic mice expressing other APOE isoforms, particularly APOE3,
the most frequent APOE allele present in humans. Although the APOE4 allele is enriched in the
AD population compared to the general population (36.7% vs. 13.7%), the major allele
represented in the AD population is APOE3 (59.4%) (48). These mice would need additional
characterization before testing because APOE3 mice have delayed Aβ onset and progression and
much less CAA compared to APOE4-expressing mice (50, 99). We anticipate that HAE-4
treatment in mice expressing APOE3 would also show reductions in Aβ plaque deposition,
because there is a similar binding affinity of HAE-4 to both APOE3 and APOE4 in vitro. It is
also possible that the therapeutic effects in APOE4 mice is stronger than in APOE3 mice if
removal of nonlipidated APOE4 compared to nonlipidated APOE3 is more protective, or if
nonlipidated APOE preferentially deposits in the plaques of APOE4 mice. Deciphering the
cellular origins, functions, and pathogenic mechanisms of poorly-lipidated APOE has great
potentials for the development of APOE immunotherapy.
Before an antibody such as HAE-4 can move into clinical trials, it would need to be
humanized and tested for safety in other species, such as nonhuman primates. A critical lesson
learned from the negative outcome of some clinical trials using Aβ immunotherapy is to
administer treatments as early as possible during the preclinical phase to prevent subsequent taumediated neurodegeneration and downstream events that are currently irreversible. To do so, the
ideal treatment strategy should be both efficacious and safe to administer chronically, as titrating
antibody doses to minimize adverse effects is identified as a source of failures in clinical trials.
In addition to no vascular complications measured by microhemorrhages, HAE-4, given at doses
5× higher than certain anti-Aβ antibodies in clinical trials were previously shown to not bind to
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circulating (lipidated) APOE, thereby minimizing potential adverse effects on lipid metabolism
that are of concern for other therapeutics targeting APOE. This suggests that patients may
tolerate a higher dose of HAE-4 compared to certain Aβ antibodies that elicit adverse effects.
Furthermore, minimal target engagement in the periphery could help sustain a reservoir of
antibodies for prolonged treatment to promote greater antibody penetrance into the brain.
Although several anti-Aβ antibodies including aducanumab remain promising potential
treatments for AD because they are undeniably efficacious in removing Aβ in certain mouse
models and the human brain, ARIA is a side effect seen in some individuals that can be
problematic. Targeting poorly-lipidated APOE, a subcomponent of both amyloid plaques and
CAA, appears to allow for retention of efficacy seen with Aβ antibodies while preventing CAArelated microhemorrhages in a mouse model. Taken together, the therapeutic effects of HAE-4
on amyloid removal and the cerebrovasculature may provide a disease-modifying treatment for
AD and CAA. Overall, our results argue a paradigm shift away from an Aβ-centric treatment
strategy and towards targeting APOE to treat AD or CAA.

5.2 Concluding remarks
The amyloid hypothesis was first proposed 30 years ago, which shined a spotlight on the
Aβ protein and steered much of the exciting research progress in AD. Indeed, recent findings
from clinical trials suggest that disease-modifying therapies targeting Aβ may have a promising
future. At the same time, the impact of downstream processes that contribute significantly to
disease progression has encouraged the development of alternative hypotheses, including
targeting the gut microbiome, innate immune system, viral infections, lipid homeostasis, as well
as renewed interest in the vascular system. To tackle a disease with such complexity, it would
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not be surprising that a combinatorial approach pursuing multiple pathogenic mechanisms will
finally lead to effective therapeutics that will prevent and cure AD.
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5.3 Figures and tables

Figure 5.1 | Reduction of fibrillar plaques/CAA and neuritic plaque tau with HAE-4
treatment
A, Schematic timeline of unilateral AD tau injection extracted from AD human brains into the
hippocampus and overlaying cortex (1 µg per injection site) of 9.5-month-old (5XFAD with
floxed APOE4+/+, 5XE4f) mice followed by 8-week weekly antibody treatment (50 mg/kg, i.p.)
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and assessment at 12-months-of-age. B–G, Staining and quantification of X34 for fibrillar
plaques and CAA (B, C), AT8 for phosphorylated tau (D, E), and Iba1 for microglia (F, G) in
the subiculum. Control = Control IgG. Data expressed as mean ± SEM, student’s t-test (twosided). *P < 0.05, **P < 0.01. No other statistical comparisons are significant unless indicated.
AD tau extracted, purified, and provided by Michael Strickland.
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